References

Ref. 1. American Association for Cancer Research®. AACR Cancer Progress Report 2024. Accessed: June 11, 2025. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2024/09/AACR_CPR_2024.pdf

Ref. 2. Siegel RL, et al. (2025) CA Cancer J Clin, 75: 10. Available from: https://doi.org/10.3322/caac.21871

Ref. 3. Giaquinto AN, et al. (2024) CA Cancer J Clin, 74: 477. Available from: https://doi.org/10.3322/caac.21863

Ref. 4. NCI Surveillance, Epidemiology, and End Results Program. NCI SEER*Explorer. Accessed: June 31, 2025. Available from: https://seer.cancer.gov/statistics-network/explorer/application.html

Ref. 5. Howlader N, et al. (2023) Cancer Epidemiol Biomarkers Prev, 32: 744. Available from: https://doi.org/10.1158/1055-9965.EPI-22-1171

Ref. 6. American Cancer Society. Cancer Facts and Figures. Accessed: June 13, 2025. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf

Ref. 7. Choueiri TK, et al. (2024) N Engl J Med, 390: 1359. Available from: https://doi.org/10.1056/NEJMoa2312695

Ref. 8. National Cancer Institute. Cancer in children and adolescents. Accessed: June 30, 2025. Available from: https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet

Ref. 9. Wagle NS, et al. (2025) CA Cancer J Clin. Available from: https://doi.org/10.3322/caac.70011

Ref. 10. Tonorezos E, et al. (2024) J Natl Cancer Inst, 116: 1784. Available from: https://doi.org/10.1093/jnci/djae135

Ref. 11. Marty S, et al. (2024) BMC Cancer, 24: 143. Available from: https://doi.org/10.1186/s12885-023-11795-1

Ref. 12. American Association for Cancer Research®. AACR Cancer Disparities Progress Report 2024. Accessed: June 14, 2025. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2024/05/AACR_CDPR2024.pdf

Ref. 13. Saka AH, et al. (2025) CA Cancer J Clin, 75: 111. Available from: https://doi.org/10.3322/caac.21874

Ref. 14. Chidiac C, et al. (2025) Pediatr Blood Cancer, 72: e31742. Available from: https://doi.org/10.1002/pbc.31742

Ref. 15. Chang CE, et al. (2025) Cancer Causes Control, 36: 605. Available from: https://doi.org/10.1007/s10552-025-01964-x

Ref. 16. Kratzer TB, et al. (2023) CA Cancer J Clin, 73: 120. Available from: https://doi.org/10.3322/caac.21757

Ref. 17. Huang AK, et al. (2024) Cancer, 130: 4306. Available from: https://doi.org/10.1002/cncr.35356

Ref. 18. Castellano T, et al. (2024) PLoS One, 19: e0307282. Available from: https://doi.org/10.1371/journal.pone.0307282

Ref. 19. Burus T, et al. (2025) J Am Coll Surg, 240: 425. Available from: https://doi.org/10.1097/XCS.0000000000001273

Ref. 20. Wu C, et al. (2024) Cancer Res Commun, 4: 2153. Available from: https://doi.org/10.1158/2767-9764.CRC-24-0177

Ref. 21. Amboree TL, et al. (2025) JAMA Netw Open, 8: e2462634. Available from: https://doi.org/10.1001/jamanetworkopen.2024.62634

Ref. 22. Alvidrez J, et al. (2019) Am J Public Health, 109: S16. Available from: https://doi.org/10.2105/AJPH.2018.304883

Ref. 23. Holder EX, et al. (2025) JAMA Netw Open, 8: e253807. Available from: https://doi.org/10.1001/jamanetworkopen.2025.3807

Ref. 24. Bade B, et al. (2025) Chest. Available from: https://doi.org/10.1016/j.chest.2025.05.004

Ref. 25. Ajjawi I, et al. (2025) Breast Cancer Res Treat, 212: 299. Available from: https://doi.org/10.1007/s10549-025-07725-3

Ref. 26. Ajjawi I, et al. (2025) Cancers (Basel), 17. Available from: https://doi.org/10.3390/cancers17091579

Ref. 27. Rode MM, et al. (2025) J Thorac Oncol. Available from: https://doi.org/10.1016/j.jtho.2025.05.009

Ref. 28. Bizuayehu HM, et al. (2024) JAMA Netw Open, 7: e2443198. Available from: https://doi.org/10.1001/jamanetworkopen.2024.43198

Ref. 29. Bizuayehu HM, et al. (2024) Cancer, 130: 3708. Available from: https://doi.org/10.1002/cncr.35458

Ref. 30. International Agency for Research on Cancer. Global Cancer Observatory. Accessed: June 30, 2025. Available from: https://globocan.iarc.fr/

Ref. 31. Bandi P, et al. (2025) Cancer Epidemiol Biomarkers Prev, 34: 836. Available from: https://doi.org/10.1158/1055-9965.EPI-24-1835

Ref. 32. Islami F, et al. (2018) CA Cancer J Clin, 68: 31. Available from: https://doi.org/10.3322/caac.21440

Ref. 33. Luo G, et al. (2025) The Lancet Respiratory Medicine. Available from: https://doi.org/10.1016/s2213-2600(24)00428-4

Ref. 34. Siegel DA, et al. (2021) JAMA Oncol, 7: 302. Available from: https://doi.org/10.1001/jamaoncol.2020.6362

Ref. 35. LoPiccolo J, et al. (2024) Nat Rev Clin Oncol, 21: 121. Available from: https://doi.org/10.1038/s41571-023-00844-0

Ref. 36. Devarakonda S, et al. (2021) J Clin Oncol, 39: 3747. Available from: https://doi.org/10.1200/JCO.21.01691

Ref. 37. Ha SY, et al. (2015) Oncotarget, 6: 5465. Available from: https://doi.org/10.18632/oncotarget.2925

Ref. 38. Dubin S, et al. (2020) Mo Med, 117: 375. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7431055/

Ref. 39. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2023-2024. Accessed: March 17, 2025. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-prevention-and-early-detection-facts-and-figures/2024-cped-files/cped-2024-cff.pdf

Ref. 40. Jemal A, et al. (2023) JAMA Oncol, 9: 1727. Available from: https://doi.org/10.1001/jamaoncol.2023.4415

Ref. 41. Rosenberg PS, et al. (2024) JAMA Netw Open, 7: e2415731. Available from: https://doi.org/10.1001/jamanetworkopen.2024.15731

Ref. 42. Sung H, et al. (2024) Lancet Public Health, 9: e583. Available from: https://doi.org/10.1016/S2468-2667(24)00156-7

Ref. 43. Afify AY, et al. (2024) Sci Rep, 14: 22041. Available from: https://doi.org/10.1038/s41598-024-71999-8

Ref. 44. Shiels MS, et al. (2025) Cancer Discov: OF1. Available from: https://doi.org/10.1158/2159-8290.CD-24-1678

Ref. 45. Li S, et al. (2023) Cancers (Basel), 15. Available from: https://doi.org/10.3390/cancers15133323

Ref. 46. Diaz-Gay M, et al. (2025) Nature. Available from: https://doi.org/10.1038/s41586-025-09025-8

Ref. 47. Chung DC, et al. (2024) N Engl J Med, 390: 973. Available from: https://doi.org/10.1056/NEJMoa2304714

Ref. 48. Seum T, et al. (2025) JAMA Intern Med, 185: 110. Available from: https://doi.org/10.1001/jamainternmed.2024.6149

Ref. 49. Giannakis M, et al. (2023) Science, 379: 1088. Available from: https://doi.org/10.1126/science.ade7114

Ref. 50. Hofseth LJ, et al. (2020) Nat Rev Gastroenterol Hepatol, 17: 352. Available from: https://doi.org/10.1038/s41575-019-0253-4

Ref. 51. Nguyen LH, et al. (2018) JNCI Cancer Spectr, 2: pky073. Available from: https://doi.org/10.1093/jncics/pky073

Ref. 52. Liu PH, et al. (2019) JAMA Oncol, 5: 37. Available from: https://doi.org/10.1001/jamaoncol.2018.4280

Ref. 53. Hur J, et al. (2021) Gut, 70: 2330. Available from: https://doi.org/10.1136/gutjnl-2020-323450

Ref. 54. Laiyemo AO, et al. (2022) Gastroenterology, 162: 1026. Available from: https://doi.org/10.1053/j.gastro.2022.01.041

Ref. 55. World Health Organization. Cancer. Accessed: June 30, 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer

Ref. 56. Bray F, et al. (2024) CA Cancer J Clin, 74: 229. Available from: https://doi.org/10.3322/caac.21834

Ref. 57. Cai Y, et al. (2025) Sci Rep, 15: 9347. Available from: https://doi.org/10.1038/s41598-025-93883-9

Ref. 58. Hughes T, et al. (2024) Lancet Oncol, 25: 1614. Available from: https://doi.org/10.1016/S1470-2045(24)00523-0

Ref. 59. Kim J, et al. (2025) Nat Med, 31: 1154. Available from: https://doi.org/10.1038/s41591-025-03502-3

Ref. 60. Wu J, et al. (2025) Journal of the National Cancer Center, 5: 322. Available from: https://doi.org/10.1016/j.jncc.2024.11.006

Ref. 61. Chen S, et al. (2023) JAMA Oncol, 9: 465. Available from: https://doi.org/10.1001/jamaoncol.2022.7826

Ref. 62. Pramesh CS, et al. (2022) Nat Med, 28: 649. Available from: https://doi.org/10.1038/s41591-022-01738-x

Ref. 63. McIntosh SA, et al. (2023) Lancet Oncol, 24: 636. Available from: https://doi.org/10.1016/S1470-2045(23)00182-1

Ref. 64. Al Sukhun SA, et al. (2024) JCO Glob Oncol, 10: e2400015. Available from: https://doi.org/10.1200/GO.24.00015

Ref. 65. Parsons SK, et al. (2023) J Clin Oncol, 41: 3260. Available from: https://doi.org/10.1200/JCO.22.01985

Ref. 66. Yabroff KR, et al. (2021) J Natl Cancer Inst, 113: 1670. Available from: https://doi.org/10.1093/jnci/djab192

Ref. 67. Islami F, et al. (2025) CA Cancer J Clin, 75: 216. Available from: https://doi.org/10.3322/caac.70005

Ref. 68. Unger JM, et al. (2023) JAMA Oncol, 9: 1371. Available from: https://doi.org/10.1001/jamaoncol.2023.2800

Ref. 69. Li M, et al. (2024) BMJ Glob Health, 9. Available from: https://doi.org/10.1136/bmjgh-2024-015700

Ref. 70. Galkina Cleary E, et al. (2023) JAMA Health Forum, 4: e230511. Available from: https://doi.org/10.1001/jamahealthforum.2023.0511

Ref. 71. Dong H, et al. (1999) Nat Med, 5: 1365. Available from: https://doi.org/10.1038/70932

Ref. 72. Freeman GJ, et al. (2000) J Exp Med, 192: 1027. Available from: https://doi.org/10.1084/jem.192.7.1027

Ref. 73. Leach DR, et al. (1996) Science, 271: 1734. Available from: https://doi.org/10.1126/science.271.5256.1734

Ref. 74. Tseng SY, et al. (2001) J Exp Med, 193: 839. Available from: https://doi.org/10.1084/jem.193.7.839

Ref. 75. Druker BJ, et al. (2001) N Engl J Med, 344: 1031. Available from: https://doi.org/10.1056/NEJM200104053441401

Ref. 76. ClinicalTrials.gov. Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ELIANA). Accessed: June 30, 2025. Available from: https://clinicaltrials.gov/study/NCT02435849

Ref. 77. Carpenter RO, et al. (2013) Clin Cancer Res, 19: 2048. Available from: https://doi.org/10.1158/1078-0432.CCR-12-2422

Ref. 78. NIH’s Role in Sustraining the US Economy 2025 Update. Accessed: July 1, 2025. Available from: https://www.unitedformedicalresearch.org/wp-content/uploads/2025/03/UMR_NIH-Role-in-Sustaining-US-Economy-FY2024-2025-Update.pdf

Ref. 79. Association of American Medical Colleges. Impact of NIH Grant Terminations. Accessed: June 30, 2025. Available from: https://www.aamc.org/about-us/mission-areas/medical-research/publication/impact-nih-grant-terminations

Ref. 80. Witze A (2025) Nature, 640: 298. Available from: https://doi.org/10.1038/d41586-025-00938-y

Ref. 81. Plackett B (2025) Nature, 640: S58. Available from: https://doi.org/10.1038/d41586-025-01152-6

Ref. 82. Baker S (2023) Nature. Available from: https://doi.org/10.1038/d41586-023-01705-7

Ref. 83. Cutler DM, et al. (2025) JAMA Health Forum, 6: e252791. Available from: https://doi.org/10.1001/jamahealthforum.2025.2791

Ref. 84. Hanahan D (2022) Cancer Discov, 12: 31. Available from: https://doi.org/10.1158/2159-8290.CD-21-1059

Ref. 85. Hanahan D, et al. (2011) Cell, 144: 646. Available from: https://doi.org/10.1016/j.cell.2011.02.013

Ref. 86. National Institutes of Health. The Office of Budget. National Institutes of Health FY 2003 – FY 2024 Distribution of Budget Authority Percentages for Basic and Applied Research. Accessed: June 11, 2025, Available from: https://officeofbudget.od.nih.gov/pdfs/FY26/spending_hist/Basic%20and%20Applied%20FY%202003%20-%20FY%202024.pdf

Ref. 87. Weinberg RA (2024) Cell, 187: 6123. Available from: https://doi.org/10.1016/j.cell.2024.09.010

Ref. 88. Skoulidis F, et al. (2025) Nat Med. Available from: https://doi.org/10.1038/s41591-025-03732-5

Ref. 89. Tripathi BK, et al. (2024) Nat Cancer, 5: 1902. Available from: https://doi.org/10.1038/s43018-024-00847-5

Ref. 90. Whitfield JR, et al. (2025) Nat Rev Drug Discov, 24: 445. Available from: https://doi.org/10.1038/s41573-025-01143-2

Ref. 91. Ivarsdottir EV, et al. (2024) Nat Genet, 56: 2422. Available from: https://doi.org/10.1038/s41588-024-01966-6

Ref. 92. Huang H, et al. (2025) Nature, 638: 528. Available from: https://doi.org/10.1038/s41586-024-08388-8

Ref. 93. Sahu S, et al. (2025) Nature, 638: 538. Available from: https://doi.org/10.1038/s41586-024-08349-1

Ref. 94. Monge C, et al. (2025) Cancers (Basel), 17. Available from: https://doi.org/10.3390/cancers17081325

Ref. 95. Selenica P, et al. (2025) NPJ Breast Cancer, 11: 70. Available from: https://doi.org/10.1038/s41523-025-00781-4

Ref. 96. Hung KL, et al. (2024) Nature, 635: 201. Available from: https://doi.org/10.1038/s41586-024-07861-8

Ref. 97. Bailey C, et al. (2024) Nature, 635: 193. Available from: https://doi.org/10.1038/s41586-024-08107-3

Ref. 98. Weiser NE, et al. (2025) Cancer Discov, 15: 1105. Available from: https://doi.org/10.1158/2159-8290.CD-25-0230

Ref. 99. Giurgiu M, et al. (2024) Genome Res, 34: 1355. Available from: https://doi.org/10.1101/gr.279123.124

Ref. 100. Zhu K, et al. (2024) Genome Res, 34: 1344. Available from: https://doi.org/10.1101/gr.279131.124

Ref. 101. Pradella D, et al. (2025) Nature, 637: 955. Available from: https://doi.org/10.1038/s41586-024-08318-8

Ref. 102. Tang J, et al. (2024) Nature, 635: 210. Available from: https://doi.org/10.1038/s41586-024-07802-5

Ref. 103. National Cancer Institute. Targeted Therapy Drug List by Cancer Type. Accessed: June 5, 2025. Available from: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/approved-drug-list

Ref. 104. Ben Mrid R, et al. (2025) Cell Death Discov, 11: 50. Available from: https://doi.org/10.1038/s41420-025-02323-0

Ref. 105. Anczukow O, et al. (2024) Nat Rev Cancer, 24: 887. Available from: https://doi.org/10.1038/s41568-024-00750-2

Ref. 106. Sanghvi N, et al. (2024) Sci Adv, 10: eadn0220. Available from: https://doi.org/10.1126/sciadv.adn0220

Ref. 107. Hamed AA, et al. (2025) Nature, 638: 499. Available from: https://doi.org/10.1038/s41586-024-08356-2

Ref. 108. Sun R, et al. (2024) Cell Rep Med, 5: 101679. Available from: https://doi.org/10.1016/j.xcrm.2024.101679

Ref. 109. Savage SR, et al. (2024) Cell, 187: 4389. Available from: https://doi.org/10.1016/j.cell.2024.05.039

Ref. 110. Martins Rodrigues F, et al. (2025) Cell, 188: 2312. Available from: https://doi.org/10.1016/j.cell.2025.03.026

Ref. 111. Zhou X, et al. (2025) EMBO Mol Med, 17: 747. Available from: https://doi.org/10.1038/s44321-025-00210-w

Ref. 112. Powell AM, et al. (2025) Oncogene. Available from: https://doi.org/10.1038/s41388-025-03315-1

Ref. 113. Zuccato JA, et al. (2025) Nat Med, 31: 116. Available from: https://doi.org/10.1038/s41591-024-03286-y

Ref. 114. Wang Q, et al. (2025) Sci Adv, 11: eadn2830. Available from: https://doi.org/10.1126/sciadv.adn2830

Ref. 115. Park MD, et al. (2024) Science, 386: eadn0327. Available from: https://doi.org/10.1126/science.adn0327

Ref. 116. Zhuang X, et al. (2025) Nature, 637: 184. Available from: https://doi.org/10.1038/s41586-024-08285-0

Ref. 117. Ledford H (2024) Nature, 631: 261. Available from: https://doi.org/10.1038/d41586-024-02107-z

Ref. 118. Brown CM, et al. (2025) Cancer Prev Res (Phila), 18: 57. Available from: https://doi.org/10.1158/1940-6207.CAPR-24-0317

Ref. 119. Supper VM, et al. (2025) Cancer Immunol Res. Available from: https://doi.org/10.1158/2326-6066.CIR-24-0876

Ref. 120. You H, et al. (2024) Front Pharmacol, 15: 1414832. Available from: https://doi.org/10.3389/fphar.2024.1414832

Ref. 121. Yang S, et al. (2025) Clin Transl Med, 15: e70313. Available from: https://doi.org/10.1002/ctm2.70313

Ref. 122. Sun M, et al. (2025) J Exp Med, 222. Available from: https://doi.org/10.1084/jem.20231954

Ref. 123. Catena X, et al. (2025) Nat Cancer, 6: 682. Available from: https://doi.org/10.1038/s43018-025-00929-y

Ref. 124. Zhu Y, et al. (2025) Cancer Cell, 43: 1045. Available from: https://doi.org/10.1016/j.ccell.2025.03.015

Ref. 125. Houlahan KE, et al. (2024) Science, 384: eadh8697. Available from: https://doi.org/10.1126/science.adh8697

Ref. 126. Gago da Graca C, et al. (2025) Sci Immunol, 10: eadn1945. Available from: https://doi.org/10.1126/sciimmunol.adn1945

Ref. 127. Thiel V, et al. (2025) Nature, 640: 1042. Available from: https://doi.org/10.1038/s41586-025-08735-3

Ref. 128. Zhi X, et al. (2025) Nature, 640: 802. Available from: https://doi.org/10.1038/s41586-025-08591-1

Ref. 129. Barron T, et al. (2025) Nature, 639: 1060. Available from: https://doi.org/10.1038/s41586-024-08579-3

Ref. 130. Peinado P, et al. (2025) Nature, 639: 765. Available from: https://doi.org/10.1038/s41586-024-08575-7

Ref. 131. Nobels A, et al. (2025) Nat Metab, 7: 895. Available from: https://doi.org/10.1038/s42255-025-01287-w

Ref. 132. Chen J, et al. (2025) Cancer Cell, 43: 361. Available from: https://doi.org/10.1016/j.ccell.2025.02.010

Ref. 133. Gilbert JA, et al. (2025) Nat Med, 31: 1099. Available from: https://doi.org/10.1038/s41591-025-03615-9

Ref. 134. Ugai S, et al. (2025) Gut Microbes, 17: 2452237. Available from: https://doi.org/10.1080/19490976.2025.2452237

Ref. 135. Zitvogel L, et al. (2025) Nat Med, 31: 1085. Available from: https://doi.org/10.1038/s41591-025-03608-8

Ref. 136. Arnone AA, et al. (2025) Cell Rep Med, 6: 101880. Available from: https://doi.org/10.1016/j.xcrm.2024.101880

Ref. 137. Guo X, et al. (2025) Mol Med, 31: 103. Available from: https://doi.org/10.1186/s10020-025-01166-w

Ref. 138. Bilal H, et al. (2025) Cancer Res, 85: 413. Available from: https://doi.org/10.1158/0008-5472.CAN-24-1609

Ref. 139. Ding T, et al. (2025) Mol Cancer, 24: 18. Available from: https://doi.org/10.1186/s12943-025-02227-8

Ref. 140. Xiao Z, et al. (2025) Nat Rev Cancer, 25: 399. Available from: https://doi.org/10.1038/s41568-025-00798-8

Ref. 141. Shiau C, et al. (2024) Nat Genet, 56: 2466. Available from: https://doi.org/10.1038/s41588-024-01890-9

Ref. 142. Tagore S, et al. (2025) Nat Med, 31: 1351. Available from: https://doi.org/10.1038/s41591-025-03530-z

Ref. 143. Xing X, et al. (2025) Cancer Cell. Available from: https://doi.org/10.1016/j.ccell.2025.03.025

Ref. 144. Bracken OV, et al. (2025) Nat Rev Drug Discov, 24: 300. Available from: https://doi.org/10.1038/s41573-024-01126-9

Ref. 145. Yang J, et al. (2025) Nature, 640: 1052. Available from: https://doi.org/10.1038/s41586-025-08626-7

Ref. 146. Arafeh R, et al. (2025) Nat Rev Cancer, 25: 59. Available from: https://doi.org/10.1038/s41568-024-00763-x

Ref. 147. Shi X, et al. (2024) Nat Cancer, 5: 1176. Available from: https://doi.org/10.1038/s43018-024-00789-y

Ref. 148. Boehm JS, et al. (2024) Cancer Discov, 14: 563. Available from: https://doi.org/10.1158/2159-8290.CD-23-1496

Ref. 149. Naddaf M (2024) Nature, 635: 14. Available from: https://doi.org/10.1038/d41586-024-03539-3

Ref. 150. de Bruijn I, et al. (2025) Nat Methods, 22: 664. Available from: https://doi.org/10.1038/s41592-025-02643-0

Ref. 151. Iglesia MD, et al. (2024) Nat Cancer, 5: 1713. Available from: https://doi.org/10.1038/s43018-024-00773-6

Ref. 152. Mo CK, et al. (2024) Nature, 634: 1178. Available from: https://doi.org/10.1038/s41586-024-08087-4

Ref. 153. Sims Z, et al. (2024) Commun Biol, 7: 409. Available from: https://doi.org/10.1038/s42003-024-06110-y

Ref. 154. Pang M, et al. (2025) Nat Methods, 22: 348. Available from: https://doi.org/10.1038/s41592-024-02513-1

Ref. 155. Baker GJ, et al. (2024) Nat Methods, 21: 2248. Available from: https://doi.org/10.1038/s41592-024-02328-0

Ref. 156. Ma C, et al. (2024) Nat Methods, 21: 2239. Available from: https://doi.org/10.1038/s41592-024-02438-9

Ref. 157. Esplin ED, et al. (2024) Nat Cancer, 5: 1737. Available from: https://doi.org/10.1038/s43018-024-00831-z

Ref. 158. Kaur H, et al. (2024) Commun Biol, 7: 1295. Available from: https://doi.org/10.1038/s42003-024-06281-8

Ref. 159. Zhu Y, et al. (2024) Nat Cancer, 5: 1697. Available from: https://doi.org/10.1038/s43018-024-00823-z

Ref. 160. Kinnersley B, et al. (2024) Nat Genet, 56: 1868. Available from: https://doi.org/10.1038/s41588-024-01785-9

Ref. 161. Lau LMS, et al. (2024) Nat Med, 30: 1913. Available from: https://doi.org/10.1038/s41591-024-03044-0

Ref. 162. Palma-Martinez MJ, et al. (2025) Nat Med, 31: 751. Available from: https://doi.org/10.1038/s41591-025-03558-1

Ref. 163. Islami F, et al. (2024) CA Cancer J Clin. Available from: https://doi.org/10.3322/caac.21858

Ref. 164. American Cancer Society. The Cancer Atlas. Accessed: June 30, 2025. Available from: https://canceratlas.cancer.org/wp-content/uploads/ACS_Atlas_Book.pdf

Ref. 165. McGee R, et al. (1994) Soc Sci Med, 38: 187. Available from: https://doi.org/10.1016/0277-9536(94)90314-x

Ref. 166. Oerlemans ME, et al. (2007) Clin Pract Epidemiol Ment Health, 3: 29. Available from: https://doi.org/10.1186/1745-0179-3-29

Ref. 167. Chida Y, et al. (2008) Nat Clin Pract Oncol, 5: 466. Available from: https://doi.org/10.1038/ncponc1134

Ref. 168. Dalton SO, et al. (2002) Eur J Cancer, 38: 1313. Available from: https://doi.org/10.1016/s0959-8049(02)00099-0

Ref. 169. Antoni MH, et al. (2023) Annu Rev Psychol, 74: 423. Available from: https://doi.org/10.1146/annurev-psych-030122-124119

Ref. 170. Mohan A, et al. (2022) Eur J Cancer Prev, 31: 585. Available from: https://doi.org/10.1097/CEJ.0000000000000752

Ref. 171. Boutelle KN, et al. (2000) Prev Med, 30: 217. Available from: https://doi.org/10.1006/pmed.1999.0618

Ref. 172. Ng DM, et al. (2003) Health Psychol, 22: 638. Available from: https://doi.org/10.1037/0278-6133.22.6.638

Ref. 173. Warnecke RB, et al. (2008) Am J Public Health, 98: 1608. Available from: https://doi.org/10.2105/AJPH.2006.102525

Ref. 174. Goel N, et al. (2024) J Clin Oncol, 42: 3618. Available from: https://doi.org/10.1200/JCO.23.02780

Ref. 175. Plascak JJ, et al. (2022) Cancer, 128: 131. Available from: https://doi.org/10.1002/cncr.33900

Ref. 176. Krueger PM, et al. (2008) Am J Public Health, 98: 889. Available from: https://doi.org/10.2105/AJPH.2007.114454

Ref. 177. American Association for Cancer Research. AACR Cancer Progress Report 2023. Accessed: Feb 29, 2025. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2023/10/AACR_CPR_2023_102423.pdf

Ref. 178. Ochiai E, et al. (2021) J Public Health Manag Pract, 27: S235. Available from: https://doi.org/10.1097/phh.0000000000001424

Ref. 179. National Center for Health Statistics. FastStats – Alcohol Use. Accessed: June 30, 2025. Available from: https://www.cdc.gov/nchs/fastats/alcohol.htm

Ref. 180. Beane Freeman LE, et al. (2022) Environ Health Perspect, 130: 57006. Available from: https://doi.org/10.1289/EHP9895

Ref. 181. Purdue MP, et al. (2023) Environ Health Perspect, 131: 77007. Available from: https://doi.org/10.1289/EHP12603

Ref. 182. Warren GW, et al. (2013) Am Soc Clin Oncol Educ Book, 33: 359. Available from: https://doi.org/10.14694/EdBook_AM.2013.33.359

Ref. 183. Jha P, et al. (2013) N Engl J Med, 368: 341. Available from: https://doi.org/10.1056/NEJMsa1211128

Ref. 184. Alexandrov LB, et al. (2016) Science, 354: 618. Available from: https://doi.org/10.1126/science.aag0299

Ref. 185. Pezzuto A, et al. (2019) Future Sci OA, 5: FSO394. Available from: https://doi.org/10.2144/fsoa-2019-0017

Ref. 186. Yang Y, et al. (2023) J Hazard Mater, 455: 131556. Available from: https://doi.org/10.1016/j.jhazmat.2023.131556

Ref. 187. Bandi P, et al. (2025) Tob Control. Available from: https://doi.org/10.1136/tc-2024-059020

Ref. 188. Arrazola RA, et al. (2025) MMWR Morb Mortal Wkly Rep, 74:118. Available from: https://doi.org/10.15585/mmwr.mm7407a3

Ref. 189. Jamal A, et al. (2024) MMWR Morb Mortal Wkly Rep, 73: 917. Available from: https://doi.org/10.15585/mmwr.mm7341a2

Ref. 190. Villanti AC, et al. (2021) Nicotine Tob Res, 23: 1318. Available from: https://doi.org/10.1093/ntr/ntaa224

Ref. 191. Delnevo CD, et al. (2011) Am J Prev Med, 41: 357. Available from: https://doi.org/10.1016/j.amepre.2011.06.039

Ref. 192. Goodwin RD, et al. (2023) Nicotine Tob Res, 25: 692. Available from: https://doi.org/10.1093/ntr/ntac214

Ref. 193. VanFrank B, et al. (2024) MMWR Morb Mortal Wkly Rep, 73: 633. Available from: https://doi.org/10.15585/mmwr.mm7329a1

Ref. 194. Khalifeh M, et al. (2024) BMJ Open, 14: e074723. Available from: https://doi.org/10.1136/bmjopen-2023-074723

Ref. 195. Marron M, et al. (2010) Int J Epidemiol, 39: 182. Available from: https://doi.org/10.1093/ije/dyp291

Ref. 196. Caturegli G, et al. (2025) JAMA Oncol, 11: 564. Available from: https://doi.org/10.1001/jamaoncol.2025.0247

Ref. 197. Cinciripini PM, et al. (2024) JAMA Oncol, 10: 1689. Available from: https://doi.org/10.1001/jamaoncol.2024.4890

Ref. 198. Anderer S (2025) JAMA, 333: 657. Available from: https://doi.org/10.1001/jama.2024.28060

Ref. 199. Rubin R (2024) JAMA, 332: 692. Available from: https://doi.org/10.1001/jama.2024.14243

Ref. 200. Yousuf H, et al. (2020) JAMA Netw Open, 3: e201177. Available from: https://doi.org/10.1001/jamanetworkopen.2020.1177

Ref. 201. Stepanek L, et al. (2022) Int J Environ Res Public Health, 19. Available from: https://doi.org/10.3390/ijerph192013152

Ref. 202. QuickStats: Trends in Secondhand Smoke Exposure Among Nonsmoking Adults, by Race and Hispanic Origin — National Health and Nutrition Examination Survey, United States, 2009–2018. MMWR Morb Mortal Wkly Rep 2021;70:224. Available from: https://doi.org/10.15585/mmwr.mm7006a6

Ref. 203. Centers for Disease Control and Prevention. Trends and Disparities in Secondhand Smoke | Smoking and Tobacco Use. Accessed: Available from: https://www.cdc.gov/tobacco/secondhand-smoke/disparities.html

Ref. 204. Erhabor J, et al. (2023) JAMA Netw Open, 6: e2340859. Available from: https://doi.org/10.1001/jamanetworkopen.2023.40859

Ref. 205. Park-Lee E, et al. (2024) MMWR Morb Mortal Wkly Rep, 73: 774. Available from: https://doi.org/10.15585/mmwr.mm7335a3

Ref. 206. Meehan J, et al. (2024) Global Pediatrics, 9: 100190. Available from: https://doi.org/10.1016/j.gpeds.2024.100190

Ref. 207. Birdsey J, et al. (2023) MMWR Morb Mortal Wkly Rep, 72: 1173. Available from: https://doi.org/10.15585/mmwr.mm7244a1

Ref. 208. Goniewicz ML, et al. (2018) JAMA Netw Open, 1: e185937. Available from: https://doi.org/10.1001/jamanetworkopen.2018.5937

Ref. 209. Herbst RS, et al. (2022) Clin Cancer Res, 28: 4861. Available from: https://doi.org/10.1158/1078-0432.CCR-22-2429

Ref. 210. Lindson N, et al. (2025) Cochrane Database of Systematic Reviews. Available from: https://doi.org/10.1002/14651858.CD010216.pub9

Ref. 211. Islami F, et al. (2018) CA Cancer J Clin, 68: 31. Available from: https://doi.org/10.3322/caac.21440

Ref. 212. Islami F, et al. (2019) JAMA Oncol, 5: 384. Available from: https://doi.org/10.1001/jamaoncol.2018.5639

Ref. 213. Emmerich SD, et al. (2024) NCHS Data Brief. Available from: https://doi.org/10.15620/cdc/159281

Ref. 214. Ng, Marie et al. (2025) Lancet, 405: 813. Available from: https://doi.org/10.1016/S0140-6736(25)00355-1

Ref. 215. Brauer, Michael et al. (2024) Lancet, 403: 2162. Available from: https://doi.org/10.1016/S0140-6736(24)00933-4

Ref. 216. Piercy KL, et al. (2018) JAMA, 320: 2020. Available from: https://doi.org/10.1001/jama.2018.14854

Ref. 217. Matthews CE, et al. (2020) Journal of Clinical Oncology, 38: 686. Available from: https://doi.org/10.1200/Jco.19.02407

Ref. 218. Patel AV, et al. (2019) Med Sci Sports Exerc, 51: 2391. Available from: https://doi.org/10.1249/MSS.0000000000002117

Ref. 219. Moore SC, et al. (2016) Jama Internal Medicine, 176: 816. Available from: https://doi.org/10.1001/jamainternmed.2016.1548

Ref. 220. Degenhardt, L, et al. (2018). The Lancet Psychiatry, 5: 987. Available from: https://doi.org/10.1016/S2215-0366(18)30337-7

Ref. 221. Clinton SK, et al. (2020) J Nutr, 150: 663. Available from: https://doi.org/10.1093/jn/nxz268

Ref. 222. Lauby-Secretan B, et al. (2016) N Engl J Med, 375: 794. Available from: https://doi.org/10.1056/NEJMsr1606602

Ref. 223. Shams-White MM, et al. (2022) Curr Dev Nutr, 6: nzac096. Available from: https://doi.org/10.1093/cdn/nzac096

Ref. 224. American Association for Cancer Research. AACR Cancer Progress Report 2022. Accessed: June 5, 2025. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2022/09/AACR_CPR_2022.pdf

Ref. 225. World Health Organization. WHO Acceleration Plan to Stop Obesity. Accessed: June 30, 2025. Available from: https://iris.who.int/bitstream/handle/10665/370281/9789240075634-eng.pdf?sequence=1

Ref. 226. Centers for Disease Control and Prevention. Adult Obesity Prevalence Maps | Obesity. Accessed: June 30, 2025. Available from: https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html

Ref. 227. Schauer DP, et al. (2017) Obesity (Silver Spring), 25 Suppl 2: S52. Available from: https://doi.org/10.1002/oby.22002

Ref. 228. Bruno DS, et al. (2020) Ann Transl Med, 8: S13. Available from: https://doi.org/10.21037/atm.2019.09.26

Ref. 229. Rubino F, et al. (2025) Lancet Diabetes Endocrinol, 13: 221. Available from: https://doi.org/10.1016/S2213-8587(24)00316-4

Ref. 230. Zamboni M, et al. (2008) Nutr Metab Cardiovasc Dis, 18: 388. Available from: https://doi.org/10.1016/j.numecd.2007.10.002

Ref. 231. Winter JE, et al. (2014) Am J Clin Nutr, 99: 875. Available from: https://doi.org/10.3945/ajcn.113.068122

Ref. 232. WHO Expert Consultation (2004) Lancet, 363: 157. Available from: https://doi.org/10.1016/S0140-6736(03)15268-3

Ref. 233. Wagner DR, et al. (2000) Am J Clin Nutr, 71: 1392. Available from: https://doi.org/10.1093/ajcn/71.6.1392

Ref. 234. Wilson RB, et al. (2023) Int J Mol Sci, 24. Available from: https://doi.org/10.3390/ijms24076192

Ref. 235. Mechanick JI, et al. (2019) Endocr Pract, 25: 1346. Available from: https://doi.org/10.4158/GL-2019-0406

Ref. 236. Collins L, et al. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. Treasure Island (FL)2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/

Ref. 237. Ryan D, et al. (2014) Obesity (Silver Spring), 22 Suppl 2: S1. Available from: https://doi.org/10.1002/oby.20819

Ref. 238. Bettadapura S, et al. (2025) Int J Obes (Lond), 49: 418. Available from: https://doi.org/10.1038/s41366-024-01500-y

Ref. 239. Rader B, et al. (2024) JAMA Health Forum, 5: e243685. Available from: https://doi.org/10.1001/jamahealthforum.2024.3685

Ref. 240. Sarma S, et al. (2022) Obesity (Silver Spring), 30: 2111. Available from: https://doi.org/10.1002/oby.23563

Ref. 241. Wang L, et al. (2024) JAMA Netw Open, 7: e2421305. Available from: https://doi.org/10.1001/jamanetworkopen.2024.21305

Ref. 242. Wolff Sagy Y, et al. (2025) EClinicalMedicine, 83: 103213. Available from: https://doi.org/10.1016/j.eclinm.2025.103213

Ref. 243. Morales-Berstein F, et al. (2024) Eur J Nutr, 63: 377. Available from: https://doi.org/10.1007/s00394-023-03270-1

Ref. 244. Jin Q, et al. (2023) Br J Cancer, 129: 1978. Available from: https://doi.org/10.1038/s41416-023-02469-7

Ref. 245. Chang K, et al. (2023) EClinicalMedicine, 56: 101840. Available from: https://doi.org/10.1016/j.eclinm.2023.101840

Ref. 246. Juul F, et al. (2022) Am J Clin Nutr, 115: 211. Available from: https://doi.org/10.1093/ajcn/nqab305

Ref. 247. Ravandi B, et al. (2025) Nat Food, 6: 296. Available from: https://doi.org/10.1038/s43016-024-01095-7

Ref. 248. Cardoso BR, et al. (2024) Age Ageing, 53. Available from: https://doi.org/10.1093/ageing/afae268

Ref. 249. Sivasubramanian BP, et al. (2023) Cureus, 15: e45324. Available from: https://doi.org/10.7759/cureus.45324

Ref. 250. Di Y, et al. (2023) BMC Cancer, 23: 782. Available from: https://doi.org/10.1186/s12885-023-11218-1

Ref. 251. Kim Y (2023) Cancer Causes Control, 34: 569. Available from: https://doi.org/10.1007/s10552-023-01698-8

Ref. 252. Meine GC, et al. (2024) Am J Gastroenterol, 119: 1056. Available from: https://doi.org/10.14309/ajg.0000000000002826

Ref. 253. Caceres-Matos R, et al. (2024) Gastrointestinal Disorders, 6: 164. Available from: https://www.mdpi.com/2624-5647/6/1/12

Ref. 254. Visioli F, et al. (2024) Lancet Reg Health Eur, 38: 100863. Available from: https://doi.org/10.1016/j.lanepe.2024.100863

Ref. 255. Ungvari Z, et al. (2025) Geroscience. Available from: https://doi.org/10.1007/s11357-025-01646-1

Ref. 256. Yang J, et al. (2024) Antioxidants (Basel), 13. Available from: https://doi.org/10.3390/antiox13070799

Ref. 257. Ghosn B, et al. (2025) Clin Nutr ESPEN, 67: 265. Available from: https://doi.org/10.1016/j.clnesp.2025.03.021

Ref. 258. Poorolajal J, et al. (2024) PLoS One, 19: e0305994. Available from: https://doi.org/10.1371/journal.pone.0305994

Ref. 259. Zhang X, et al. (2025) BMC Gastroenterol, 25: 332. Available from: https://doi.org/10.1186/s12876-025-03948-2

Ref. 260. Zhao L, et al. (2023) JAMA, 330: 537. Available from: https://doi.org/10.1001/jama.2023.12618

Ref. 261. Feng L, et al. (2023) Eur J Clin Nutr, 77: 941. Available from: https://doi.org/10.1038/s41430-023-01302-x

Ref. 262. de Lorgeril M, et al. (2020) Transl Cancer Res, 9: 3172. Available from: https://doi.org/10.21037/tcr-2020-003

Ref. 263. McCullough ML, et al. (2022) Cancer Epidemiol Biomarkers Prev, 31: 1907. Available from: https://doi.org/10.1158/1055-9965.EPI-22-0392

Ref. 264. Tseng TS, et al. (2021) World J Diabetes, 12: 1530. Available from: https://doi.org/10.4239/wjd.v12.i9.1530

Ref. 265. Heo GY, et al. (2024) JAMA Netw Open, 7: e2356885. Available from: https://doi.org/10.1001/jamanetworkopen.2023.56885

Ref. 266. Cai XY, et al. (2022) Clin Kidney J, 15: 718. Available from: https://doi.org/10.1093/ckj/sfab227

Ref. 267. Gomez-Castillo L, et al. (2025) JAMA Otolaryngol Head Neck Surg, 151: 450. Available from: https://doi.org/10.1001/jamaoto.2024.5252

Ref. 268. Hua SV, et al. (2023) Jama Network Open, 6: e2323200. Available from: https://doi.org/10.1001/jamanetworkopen.2023.23200

Ref. 269. Kaplan S, et al. (2024) JAMA Health Forum, 5: e234737. Available from: https://doi.org/10.1001/jamahealthforum.2023.4737

Ref. 270. Bleich SN, et al. (2021) JAMA Netw Open, 4: e2113527. Available from: https://doi.org/10.1001/jamanetworkopen.2021.13527

Ref. 271. Liu EF, et al. (2025) JAMA Netw Open, 8: e2456170. Available from: https://doi.org/10.1001/jamanetworkopen.2024.56170

Ref. 272. Gregory EF, et al. (2025) JAMA Pediatr, 179: 46. Available from: https://doi.org/10.1001/jamapediatrics.2024.4782

Ref. 273. Bui LP, et al. (2024) Am J Clin Nutr, 120: 80. Available from: https://doi.org/10.1016/j.ajcnut.2024.03.019

Ref. 274. Cai Y, et al. (2024) Am J Clin Nutr, 119: 406. Available from: https://doi.org/10.1016/j.ajcnut.2023.11.015

Ref. 275. Dall TM, et al. (2024) Nutr Diabetes, 14: 96. Available from: https://doi.org/10.1038/s41387-024-00352-9

Ref. 276. Lopez-Bueno R, et al. (2023) JAMA Intern Med, 183: 982. Available from: https://doi.org/10.1001/jamainternmed.2023.3093

Ref. 277. Minihan AK, et al. (2022) Med Sci Sports Exerc, 54: 417. Available from: https://doi.org/10.1249/MSS.0000000000002801

Ref. 278. Shreves AH, et al. (2025) Br J Sports Med, 59: 839. Available from: https://doi.org/10.1136/bjsports-2024-109360

Ref. 279. Courneya KS, et al. (2025) N Engl J Med, 393: 13. Available from: https://doi.org/10.1056/NEJMoa2502760

Ref. 280. Elgaddal N, et al. (2024) Natl Health Stat Report. Available from: https://doi.org/10.15620/cdc/166708

Ref. 281. Fokom Domgue J, et al. (2025) JAMA Oncol. Available from: https://doi.org/10.1001/jamaoncol.2025.1146

Ref. 282. Naudin S, et al. (2025) PLoS Med, 22: e1004590. Available from: https://doi.org/10.1371/journal.pmed.1004590

Ref. 283. Terry MB, et al. (2024) Breast Cancer Res, 26: 179. Available from: https://doi.org/10.1186/s13058-024-01937-z

Ref. 284. Alcohol and Cancer Risk: The US Surgeon General’s Advisory. Alcohol and Cancer Risk: The US Surgeon General’s Advisory. Washington (DC) 2025. Available from: https://www.hhs.gov/surgeongeneral/reports-and-publications/alcohol-cancer/index.html

Ref. 285. Zhao J, et al. The effects of alcohol warning labels on population alcohol consumption: An interrupted time series analysis of alcohol sales in Yukon, Canada. Journal of Studies on Alcohol and Drugs. Volume 81: Alcohol Research Documentation Inc.; 2020. p 225. Available from: https://www.jsad.com/doi/10.15288/jsad.2020.81.225

Ref. 286. Phillips JA (2021) Workplace Health Saf, 69: 395. Available from: https://doi.org/10.1177/21650799211026980

Ref. 287. Hosseinpour Z, et al. (2025) J Racial Ethn Health Disparities. Available from: https://doi.org/10.1007/s40615-025-02399-5

Ref. 288. Rezaei SJ, et al. (2024) JAMA Dermatol, 160: 1107. Available from: https://doi.org/10.1001/jamadermatol.2024.3043

Ref. 289. Wei G, et al. (2025) J Invest Dermatol, 145: 876. Available from: https://doi.org/10.1016/j.jid.2024.04.038

Ref. 290. Bowers JM, et al. (2020) Am J Public Health, 110: 823. Available from: https://doi.org/10.2105/AJPH.2020.305605

Ref. 291. Centers for Disease Control and Prevention. 2025 Viral Hepatitis National Progress Report Overview | Viral Hepatitis. Accessed: June 30, 2025. Available from: https://www.cdc.gov/hepatitis/php/npr-2025/overview.html

Ref. 292. World Cancer Report: Cancer research for cancer prevention. In: Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: Cancer research for cancer prevention. Lyon (FR)2020. Available from: https://publications.iarc.who.int/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-Cancer-Research-For-Cancer-Prevention-2020

Ref. 293. American Cancer Society. Global Cancer Facts and Figures 5th Edition. Accessed: June 30, 2025. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf

Ref. 294. Munoz N, et al. (2003) N Engl J Med, 348: 518. Available from: https://doi.org/10.1056/NEJMoa021641

Ref. 295. de Martel C, et al. (2017) Int J Cancer, 141: 664. Available from: https://doi.org/10.1002/ijc.30716

Ref. 296. Pingali C, et al. (2024) MMWR Morb Mortal Wkly Rep, 73: 708. Available from: https://doi.org/10.15585/mmwr.mm7333a1

Ref. 297. Anderer S (2025) JAMA, 333: 1385. Available from: https://doi.org/10.1001/jama.2025.2573

Ref. 298. Gargano JW, et al. (2025) MMWR Morb Mortal Wkly Rep, 74:96. Available from: https://doi.org/10.15585/mmwr.mm7406a4

Ref. 299. Gallagher TJ, et al. (2024) Otolaryngol Head Neck Surg, 171: 1780. Available from: https://doi.org/10.1002/ohn.952

Ref. 300. Centers for Disease Control and Prevetion. Cancer Statistics At a Glance. Accessed: March 17, 2025. Available from: https://gis.cdc.gov/Cancer/USCS/#/AtAGlance

Ref. 301. Centers for Disease Control and Prevention. 2023 Viral Hepatitis Surveillance Report | 2023 Hepatitis Surveillance. Accessed: June 30, 2025. Available from: https://www.cdc.gov/hepatitis-surveillance-2023/about/index.html

Ref. 302. Li D, et al. (2024) Gastro Hep Adv, 3: 749. Available from: https://doi.org/10.1016/j.gastha.2024.04.008

Ref. 303. Kumar S, et al. (2020) Gastroenterology, 158: 527. Available from: https://doi.org/10.1053/j.gastro.2019.10.019

Ref. 304. Parsonnet J, et al. (1994) N Engl J Med, 330: 1267. Available from: https://doi.org/10.1056/NEJM199405053301803

Ref. 305. Stathis A, et al. (2009) Ann Oncol, 20: 1086. Available from: https://doi.org/10.1093/annonc/mdn760

Ref. 306. Kiesewetter B, et al. (2013) Blood, 122: 1350. Available from: https://doi.org/10.1182/blood-2013-02-486522

Ref. 307. Garman KS, et al. (2024) Gastric Cancer, 27: 28. Available from: https://doi.org/10.1007/s10120-023-01448-4

Ref. 308. Zhang Y, et al. (2025) BMC Public Health, 25: 1260. Available from: https://doi.org/10.1186/s12889-025-22450-8

Ref. 309. Hill W, et al. (2023) Nature, 616: 159. Available from: https://doi.org/10.1038/s41586-023-05874-3

Ref. 310. Wu AH, et al. (2025) J Clin Oncol, 43: 273. Available from: https://doi.org/10.1200/JCO.24.00418

Ref. 311. Chan FY, et al. (2025) PLOS Glob Public Health, 5: e0004357. Available from: https://doi.org/10.1371/journal.pgph.0004357

Ref. 312. Chang CJ, et al. (2022) J Natl Cancer Inst, 114: 1636. Available from: https://doi.org/10.1093/jnci/djac165

Ref. 313. Bertrand KA, et al. (2023) Environ Res, 239: 117228. Available from: https://doi.org/10.1016/j.envres.2023.117228

Ref. 314. Llanos AAM, et al. (2017) Carcinogenesis, 38: 883. Available from: https://doi.org/10.1093/carcin/bgx060

Ref. 315. Parrish M, et al. (2025) Nat Rev Cancer. Available from: https://doi.org/10.1038/s41568-025-00854-3

Ref. 316. Morris RD (1995) Environ Health Perspect, 103 Suppl 8: 225. Available from: https://doi.org/10.1289/ehp.95103s8225

Ref. 317. Levin R, et al. (2024) J Expo Sci Environ Epidemiol, 34: 3. Available from: https://doi.org/10.1038/s41370-023-00597-z

Ref. 318. van Gerwen M, et al. (2023) EBioMedicine, 97: 104831. Available from: https://doi.org/10.1016/j.ebiom.2023.104831

Ref. 319. Liu B, et al. (2024) JAMA Netw Open, 7: e243127. Available from: https://doi.org/10.1001/jamanetworkopen.2024.3127

Ref. 320. Rhee J, et al. (2024) Environ Int, 192: 109058. Available from: https://doi.org/10.1016/j.envint.2024.109058

Ref. 321. Hu XC, et al. (2016) Environ Sci Technol Lett, 3: 344. Available from: https://doi.org/10.1021/acs.estlett.6b00260

Ref. 322. Zahm S, et al. (2024) Lancet Oncol, 25: 16. Available from: https://doi.org/10.1016/S1470-2045(23)00622-8

Ref. 323. Yazzie SA, et al. (2020) Int J Environ Res Public Health, 17: 2813. Available from: https://doi.org/10.3390/ijerph17082813

Ref. 324. Centers for Disease Control and Prevention. Raising Radon Awareness in Tribal Communities | Radon. Accessed: June 30, 2025. Available from: https://www.cdc.gov/radon/features/tribal-communities.html

Ref. 325. Riudavets M, et al. (2022) Cancers (Basel), 14: 3142. Available from: https://doi.org/10.3390/cancers14133142

Ref. 326. Liu Y, et al. (2024) Crit Rev Oncol Hematol, 198: 104363. Available from: https://doi.org/10.1016/j.critrevonc.2024.104363

Ref. 327. United States Environmental Protection Agency. Health Risk of Radon. Accessed: June 7, 2025. Available from: https://www.epa.gov/radon/health-risk-radon

Ref. 328. US Global Change Research Program. Fourth National Climate Assessment. Volume II: Impacts, Risks, and Adaptation in the United States. Accessed: March 17, 2025. Available from: https://nca2018.globalchange.gov/downloads/NCA2018_FullReport.pdf

Ref. 329. Hvidtfeldt UA, et al. (2023) Cancer Epidemiol Biomarkers Prev, 32: 105. Available from: https://doi.org/10.1158/1055-9965.EPI-22-0720

Ref. 330. Smotherman C, et al. (2023) Breast Cancer Res, 25: 83. Available from: https://doi.org/10.1186/s13058-023-01681-w

Ref. 331. Cannataro VL, et al. (2025) Cancer, 131: e35732. Available from: https://doi.org/10.1002/cncr.35732

Ref. 332. Chartres N, et al. (2024) Environ Sci Technol, 58: 22843. Available from: https://doi.org/10.1021/acs.est.3c09524

Ref. 333. Jani CT, et al. (2025) EClinicalMedicine, 79: 103033. Available from: https://doi.org/10.1016/j.eclinm.2024.103033

Ref. 334. Myers R, et al. (2021) J Thorac Oncol, 16: 1850. Available from: https://doi.org/10.1016/j.jtho.2021.06.015

Ref. 335. West M, et al. (2024) J Occup Environ Hyg, 21: 741. Available from: https://doi.org/10.1080/15459624.2024.2388532

Ref. 336. Jephcote C, et al. (2020) Environ Health, 19: 53. Available from: https://doi.org/10.1186/s12940-020-00582-1

Ref. 337. Cheng I, et al. (2022) Am J Respir Crit Care Med, 206: 1008. Available from: https://doi.org/10.1164/rccm.202107-1770OC

Ref. 338. Carroll R, et al. (2023) Environ Res, 239: 117349. Available from: https://doi.org/10.1016/j.envres.2023.117349

Ref. 339. American Lung Association. State of the Air 2023 Report. Accessed: March 17, 2025. Available from: https://www.lung.org/getmedia/338b0c3c-6bf8-480f-9e6e-b93868c6c476/SOTA-2023.pdf

Ref. 340. Bradley AC, et al. (2024) Environ Sci Technol, 58: 4226. Available from: https://doi.org/10.1021/acs.est.3c03230

Ref. 341. Tessum CW, et al. (2021) Sci Adv, 7: eabf4491. Available from: https://doi.org/10.1126/sciadv.abf4491

Ref. 342. Maruzzo AJ, et al. (2025) Environ Health Perspect, 133: 17002. Available from: https://doi.org/10.1289/EHP14721

Ref. 343. Baan R, et al. (2009) Lancet Oncol, 10: 1143. Available from: https://doi.org/10.1016/s1470-2045(09)70358-4

Ref. 344. McDermott JE, et al. (2024) J Proteome Res, 23: 1547. Available from: https://doi.org/10.1021/acs.jproteome.3c00418

Ref. 345. National Toxicology Program. NTP Cancer Hazard Assessment Report on Night Shift Work and Light at Night. NTP Cancer Hazard Assessment Report on Night Shift Work and Light at Night. Research Triangle Park (NC): National Toxicology Program; 2021. Available from: https://pubmed.ncbi.nlm.nih.gov/34197056/

Ref. 346. National Toxicology Program. National Toxicology Program Cancer Hazard Assessment Report on Night Shift Work and Light at Night. Accessed: June 5, 2025. Available from: https://ntp.niehs.nih.gov/sites/default/files/ntp/results/pubs/cancer_assessment/lanfinal20210400_508.pdf

Ref. 347. Phillips KA, et al. (2025) J Clin Oncol, 43: 422. Available from: https://doi.org/10.1200/JCO.24.00176

Ref. 348. Nichols HB, et al. (2019) Ann Intern Med, 170: 22. Available from: https://doi.org/10.7326/M18-1323

Ref. 349. Ambrosone CB, et al. (2020) Cancer Res, 80: 4871. Available from: https://doi.org/10.1158/0008-5472.CAN-20-0077

Ref. 350. Jung AY, et al. (2022) J Natl Cancer Inst, 114: 1706. Available from: https://doi.org/10.1093/jnci/djac117

Ref. 351. Proussaloglou EM, et al. (2023) Pathol Res Pract, 244: 154413. Available from: https://doi.org/10.1016/j.prp.2023.154413

Ref. 352. Vohra SN, et al. (2022) Cancer Epidemiol Biomarkers Prev, 31:561. Available from: https://doi.org/10.1158/1055-9965.EPI-21-0940

Ref. 353. John EM, et al. (2024) Breast Cancer Res, 26: 88. Available from: https://doi.org/10.1186/s13058-024-01834-5

Ref. 354. Millikan RC, et al. (2008) Breast Cancer Res Treat, 109: 123. Available from: https://doi.org/10.1007/s10549-007-9632-6

Ref. 355. Lord SJ, et al. (2008) Cancer Epidemiol Biomarkers Prev, 17: 1723. Available from: https://doi.org/10.1158/1055-9965.EPI-07-2824

Ref. 356. Fortner RT, et al. (2019) Breast Cancer Res, 21: 40. Available from: https://doi.org/10.1186/s13058-019-1119-y

Ref. 357. Masi AC, et al. (2024) Microb Biotechnol, 17: e14520. Available from: https://doi.org/10.1111/1751-7915.14520

Ref. 358. Anstey EH, et al. (2017) Am J Prev Med, 53: S40. Available from: https://doi.org/10.1016/j.amepre.2017.04.024

Ref. 359. Palmer JR, et al. (2014) J Natl Cancer Inst, 106: dju237. Available from: https://doi.org/10.1093/jnci/dju237

Ref. 360. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project. Expert Report 2018. Lactation and the Risk of Cancer. Accessed: June 6, 2025. Available from: https://www.wcrf.org/diet-activity-and-cancer/

Ref. 361. Babic A, et al. (2020) JAMA Oncol, 6: e200421. Available from: https://doi.org/10.1001/jamaoncol.2020.0421

Ref. 362. Chlebowski RT, et al. (2024) J Clin Oncol, 42: 3537. Available from: https://doi.org/10.1200/JCO.23.01918

Ref. 363. Chlebowski RT, et al. (2020) JAMA, 324: 369. Available from: https://doi.org/10.1001/jama.2020.9482

Ref. 364. Chlebowski RT, et al. (2008) Arch Intern Med, 168: 370. Available from: https://doi.org/10.1001/archinternmed.2007.123

Ref. 365. Chlebowski RT, et al. (2009) N Engl J Med, 360: 573. Available from: https://doi.org/10.1056/NEJMoa0807684

Ref. 366. Collaborative Group on Hormonal Factors in Breast Cancer. (2019) Lancet, 394: 1159. Available from: https://doi.org/10.1016/S0140-6736(19)31709-X

Ref. 367. Wang Y, et al. (2025) J Natl Cancer Inst, 117: 1260. Available from: https://doi.org/10.1093/jnci/djaf051

Ref. 368. Jackson SS, et al. (2022) Trends Cancer, 8: 273. Available from: https://doi.org/10.1016/j.trecan.2022.01.005

Ref. 369. de Blok CJM, et al. (2019) BMJ, 365: l1652. Available from: https://doi.org/10.1136/bmj.l1652

Ref. 370. de Nie I, et al. (2020) J Clin Endocrinol Metab, 105: e3293. Available from: https://doi.org/10.1210/clinem/dgaa412

Ref. 371. Vestering A, et al. (2025) EClinicalMedicine, 80: 103037. Available from: https://doi.org/10.1016/j.eclinm.2024.103037

Ref. 372. American Association for Cancer Research. AACR Cancer Progress Report 2021. Accessed: June 30, 2025. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2021/10/AACR_CPR_2021.pdf

Ref. 373. Knudsen MD, et al. (2025) JAMA Oncol, 11: 46. Available from: https://doi.org/10.1001/jamaoncol.2024.5227

Ref. 374. Huang S, et al. (2025) JAMA Netw Open, 8: e255322. Available from: https://doi.org/10.1001/jamanetworkopen.2025.5322

Ref. 375. Halpern MT, et al. (2024) Ann Intern Med, 177: 1170. Available from: https://doi.org/10.7326/M24-0375

Ref. 376. Lange JM, et al. (2025) Am J Epidemiol, 194: 441. Available from: https://doi.org/10.1093/aje/kwae245

Ref. 377. US Food and Drug Administration. FDA Updates Mammography Regulations to Require Reporting of Breast Density Information and Enhance Facility Oversight | FDA. Accessed: June 5, 2025. Available from: https://www.fda.gov/news-events/press-announcements/fda-updates-mammography-regulations-require-reporting-breast-density-information-and-enhance

Ref. 378. Siddique S, et al. (2024) JAMA Netw Open, 7: e2436358. Available from: https://doi.org/10.1001/jamanetworkopen.2024.36358

Ref. 379. Lv XH, et al. (2025) Am J Gastroenterol. Available from: https://doi.org/10.14309/ajg.0000000000003429

Ref. 380. Doubeni CA, et al. (2024) JAMA Netw Open, 7: e2423671. Available from: https://doi.org/10.1001/jamanetworkopen.2024.23671

Ref. 381. Carvalho B, et al. (2025) Gastroenterology, 168: 121. Available from: https://doi.org/10.1053/j.gastro.2024.08.022

Ref. 382. Nascimento de Lima P, et al. (2025) JAMA Netw Open, 8: e2454938. Available from: https://doi.org/10.1001/jamanetworkopen.2024.54938

Ref. 383. Kim U, et al. (2024) JAMA Netw Open, 7: e2439263. Available from: https://doi.org/10.1001/jamanetworkopen.2024.39263

Ref. 384. Zhang-Petersen C, et al. (2024) JAMA Netw Open, 7: e2452688. Available from: https://doi.org/10.1001/jamanetworkopen.2024.52688

Ref. 385. Hendrick RE, et al. (2011) AJR Am J Roentgenol, 196: W112. Available from: https://doi.org/10.2214/AJR.10.5609

Ref. 386. Gagrat ZD, et al. (2024) Cancer Prev Res (Phila), 17: 119. Available from: https://doi.org/10.1158/1940-6207.CAPR-23-0285

Ref. 387. Kim SY, et al. (2024) Radiology, 312: e242008. Available from: https://doi.org/10.1148/radiol.242008

Ref. 388. Philpotts LE, et al. (2024) Radiology, 312: e232841. Available from: https://doi.org/10.1148/radiol.232841

Ref. 389. Li T, et al. (2025) JAMA Oncol. Available from: https://doi.org/10.1001/jamaoncol.2025.1209

Ref. 390. LeLaurin JH, et al. (2025) BMJ Qual Saf. Available from: https://doi.org/10.1136/bmjqs-2025-018558

Ref. 391. American Cancer Society Cancer Action Network. National Screening Survey. Accessed: June 30, 2025. Available from: https://www.fightcancer.org/policy-resources/national-screening-survey

Ref. 392. Mohl JT, et al. (2023) JAMA Netw Open, 6: e2251384. Available from: https://doi.org/10.1001/jamanetworkopen.2022.51384

Ref. 393. Alagoz O, et al. (2024) J Natl Cancer Inst, 116: 1807. Available from: https://doi.org/10.1093/jnci/djae140

Ref. 394. Lawson MB, et al. (2025) Radiology, 314: e241673. Available from: https://doi.org/10.1148/radiol.241673

Ref. 395. Sedani AE, et al. (2025) JAMA Netw Open, 8: e2449556. Available from: https://doi.org/10.1001/jamanetworkopen.2024.49556

Ref. 396. Gudina AT, et al. (2025) Cancer Epidemiol Biomarkers Prev, 34:35. Available from: https://doi.org/10.1158/1055-9965.EPI-24-0725

Ref. 397. Amiri S, et al. (2025) Ann Intern Med, 178: 177. Available from: https://doi.org/10.7326/M24-0124

Ref. 398. Gu T, et al. (2024) JAMA Netw Open, 7: e2451827. Available from: https://doi.org/10.1001/jamanetworkopen.2024.51827

Ref. 399. Zhang H, et al. (2025) Cancer, 131: e35852. Available from: https://doi.org/10.1002/cncr.35852

Ref. 400. Gopalani SV, et al. (2025) Cancer Epidemiol, 97: 102851. Available from: https://doi.org/10.1016/j.canep.2025.102851

Ref. 401. Paudel YR, et al. (2025) Journal of Public Health. Available from: https://doi.org/10.1007/s10389-025-02446-9

Ref. 402. The ASCO Post. 20-Year Screening Program Drives Down Colorectal Cancer Cases, Deaths. Accessed: June 30, 2025. Available from: https://ascopost.com/news/may-2025/20-year-screening-program-drives-down-colorectal-cancer-cases-deaths/

Ref. 403. McClellan SP, et al. (2024) J Am Board Fam Med, 37: 660. Available from: https://doi.org/10.3122/jabfm.2023.230399R1

Ref. 404. Karanth SD, et al. (2024) J Thorac Dis, 16: 7143. Available from: https://doi.org/10.21037/jtd-24-846

Ref. 405. Pelzl CE, et al. (2025) Clin Breast Cancer, 25: e288. Available from: https://doi.org/10.1016/j.clbc.2024.11.012

Ref. 406. Chan RJ, et al. (2023) CA Cancer J Clin, 73: 565. Available from: https://doi.org/10.3322/caac.21788

Ref. 407. Baggett TP, et al. (2024) JAMA Intern Med, 184: 892. Available from: https://doi.org/10.1001/jamainternmed.2024.1662

Ref. 408. Jang J, et al. (2025) J Gen Intern Med. Available from: https://doi.org/10.1007/s11606-025-09566-8

Ref. 409. Reuland DS, et al. (2024) JAMA Netw Open, 7: e2446693. Available from: https://doi.org/10.1001/jamanetworkopen.2024.46693

Ref. 410. Montealegre JR, et al. (2025) JAMA Intern Med. Available from: https://doi.org/10.1001/jamainternmed.2025.2971

Ref. 411. The White House. Enhancing Patient Navigation with Technology to Improve Equity in Cancer Care: A Report to the President of the United States from the President’s Cancer Panel. Accessed: June 30, 2025. Available from: https://prescancerpanel.cancer.gov/reports-meetings/enhancing-patient-navigation-2024/presidents-cancer-panel-2024-report.pdf

Ref. 412. Okasako-Schmucker DL, et al. (2023) Am J Prev Med, 64: 579. Available from: https://doi.org/10.1016/j.amepre.2022.10.016

Ref. 413. Subramanian S, et al. (2024) Health Promot Pract: 15248399241303891. Available from: https://doi.org/10.1177/15248399241303891

Ref. 414. Bekteshi V, et al. (2024) J Prim Care Community Health, 15: 21501319241295916. Available from: https://doi.org/10.1177/21501319241295916

Ref. 415. Cofie LE, et al. (2024) J Racial Ethn Health Disparities. Available from: https://doi.org/10.1007/s40615-024-02231-6

Ref. 416. Pignone M, et al. (2025) Am J Prev Med, 68: 227. Available from: https://doi.org/10.1016/j.amepre.2024.09.016

Ref. 417. Lopez A, et al. (2024) J Racial Ethn Health Disparities. Available from: https://doi.org/10.1007/s40615-024-02085-y

Ref. 418. Hernstrom V, et al. (2025) Lancet Digit Health, 7: e175. Available from: https://doi.org/10.1016/S2589-7500(24)00267-X

Ref. 419. Friedewald SM, et al. (2025) Breast Cancer Res Treat, 211: 1. Available from: https://doi.org/10.1007/s10549-025-07616-7

Ref. 420. Eisemann N, et al. (2025) Nat Med, 31: 917. Available from: https://doi.org/10.1038/s41591-024-03408-6

Ref. 421. Hirsch L, et al. (2025) Acad Radiol, 32: 1218. Available from: https://doi.org/10.1016/j.acra.2024.10.014

Ref. 422. Jiang S, et al. (2025) JAMA Netw Open, 8: e2512681. Available from: https://doi.org/10.1001/jamanetworkopen.2025.12681

Ref. 423. Sardanelli F, et al. (2024) Insights Imaging, 15: 96. Available from: https://doi.org/10.1186/s13244-024-01653-4

Ref. 424. US Food and Drug Administration. Device Classification Under Section 513(f)(2)(De Novo). Accessed: June 30, 2025. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN240047

Ref. 425. Makar J, et al. (2025) Gastrointest Endosc, 101: 68. Available from: https://doi.org/10.1016/j.gie.2024.08.033

Ref. 426. Seager A, et al. (2024) Lancet Gastroenterol Hepatol, 9: 911. Available from: https://doi.org/10.1016/S2468-1253(24)00161-4

Ref. 427. Geppert J, et al. (2024) Thorax, 79: 1040. Available from: https://doi.org/10.1136/thorax-2024-221662

Ref. 428. Diaz O, et al. (2024) Eur J Radiol, 175: 111457. Available from: https://doi.org/10.1016/j.ejrad.2024.111457

Ref. 429. Fitzpatrick MB, et al. (2025) JAMA Netw Open, 8: e2511081. Available from: https://doi.org/10.1001/jamanetworkopen.2025.11081

Ref. 430. National Cancer Institute. SHIP Trial – About the Study. Accessed: June 30, 2025. Available from: https://prevention.cancer.gov/research-areas/networks-consortia-programs/last-mile/ship-trial

Ref. 431. Bao H, et al. (2025) Nat Med. Available from: https://doi.org/10.1038/s41591-025-03735-2

Ref. 432. Montoya Mira JL, et al. (2025) Sci Transl Med, 17: eadq3110. Available from: https://doi.org/10.1126/scitranslmed.adq3110

Ref. 433. Alix-Panabieres C, et al. (2025) Cancer Cell, 43: 161. Available from: https://doi.org/10.1016/j.ccell.2024.11.009

Ref. 434. Carethers JM (2024) N Engl J Med, 390: 1045. Available from: https://doi.org/10.1056/NEJMe2400366

Ref. 435. Perachino M, et al. (2025) Commun Med (Lond), 5: 167. Available from: https://doi.org/10.1038/s43856-025-00885-9

Ref. 436. Semenkovich NP, et al. (2024) JAMA Oncol, 10: 1023. Available from: https://doi.org/10.1001/jamaoncol.2024.1860

Ref. 437. Parillo M, et al. (2025) Cancers (Basel), 17. Available from: https://doi.org/10.3390/cancers17020275

Ref. 438. Bilreiro C, et al. (2025) Invest Radiol, 60: 397. Available from: https://doi.org/10.1097/RLI.0000000000001142

Ref. 439. Rebello RJ, et al. (2021) Nat Rev Dis Primers, 7: 9. Available from: https://doi.org/10.1038/s41572-020-00243-0

Ref. 440. Launer BM, et al. (2025) Urol Oncol, 43: 15. Available from: https://doi.org/10.1016/j.urolonc.2024.05.012

Ref. 441. Hugosson J, et al. (2024) N Engl J Med, 391: 1083. Available from: https://doi.org/10.1056/NEJMoa2406050

Ref. 442. Hamm CA, et al. (2025) JAMA Oncol, 11: 145. Available from: https://doi.org/10.1001/jamaoncol.2024.5497

Ref. 443. Yang X, et al. (2023) Nat Rev Cancer, 23: 619. Available from: https://doi.org/10.1038/s41568-023-00599-x

Ref. 444. Roberts E, et al. (2023) Breast, 67: 71. Available from: https://doi.org/10.1016/j.breast.2023.01.003

Ref. 445. McHugh JK, et al. (2025) N Engl J Med, 392: 1406. Available from: https://doi.org/10.1056/NEJMoa2407934

Ref. 446. Kachuri L, et al. (2020) Nat Commun, 11: 6084. Available from: https://doi.org/10.1038/s41467-020-19600-4

Ref. 447. Mallabar-Rimmer B, et al. (2024) Eur J Hum Genet, 32: 1456. Available from: https://doi.org/10.1038/s41431-024-01654-3

Ref. 448. Leoni G, et al. (2020) Cancer Res, 80: 3972. Available from: https://doi.org/10.1158/0008-5472.CAN-20-1072

Ref. 449. Domchek SM, et al. (2025) Journal of Clinical Oncology, 43: 10505. Available from: https://doi.org/10.1200/JCO.2025.43.16_suppl.10505

Ref. 450. Zhang J, et al. (2015) N Engl J Med, 373: 2336. Available from: https://doi.org/10.1056/NEJMoa1508054

Ref. 451. Parsons DW, et al. (2016) JAMA Oncol, 2: 616. Available from: https://doi.org/10.1001/jamaoncol.2015.5699

Ref. 452. Grobner SN, et al. (2018) Nature, 555: 321. Available from: https://doi.org/10.1038/nature25480

Ref. 453. Brodeur GM, et al. (2017) Clin Cancer Res, 23: e1. Available from: https://doi.org/10.1158/1078-0432.CCR-17-0702

Ref. 454. Brodeur GM, et al. (2025) Clin Cancer Res. Available from: https://doi.org/10.1158/1078-0432.CCR-25-0423

Ref. 455. Abu Rous F, et al. (2024) JAMA Oncol, 10: 416. Available from: https://doi.org/10.1001/jamaoncol.2023.5778

Ref. 456. Abdou Y, et al. (2024) J Clin Oncol, 42: 3887. Available from: https://doi.org/10.1200/JCO-24-01484

Ref. 457. Unger JM, et al. (2024) J Clin Oncol, 42: 3917. Available from: https://doi.org/10.1200/JCO.24.00843

Ref. 458. Adashek JJ, et al. (2019) Nat Rev Clin Oncol, 16: 773. Available from: https://doi.org/10.1038/s41571-019-0262-9

Ref. 459. Kingwell K (2022) Nat Rev Drug Discov, 21: 702. Available from: https://doi.org/10.1038/d41573-022-00144-9

Ref. 460. Ouimet C, et al. (2025) J Natl Cancer Inst, 117: 1056. Available from: https://doi.org/10.1093/jnci/djaf013

Ref. 461. Sledge GW, Jr., et al. (2025) Nat Commun, 16: 2646. Available from: https://doi.org/10.1038/s41467-025-57941-0

Ref. 462. Nikanjam M, et al. (2025) CA Cancer J Clin, 75: 243. Available from: https://doi.org/10.3322/caac.21880

Ref. 463. Wagner MJ, et al. (2021) J Immunother Cancer, 9. Available from: https://doi.org/10.1136/jitc-2021-002990

Ref. 464. Wang H, et al. (2019) Curr Breast Cancer Rep, 11: 303. Available from: https://doi.org/10.1007/s12609-019-00334-2

Ref. 465. Dy GK, et al. (2023) J Clin Oncol, 41: 3311. Available from: https://doi.org/10.1200/JCO.22.02524

Ref. 466. Sicklick JK, et al. (2021) Genome Med, 13: 155. Available from: https://doi.org/10.1186/s13073-021-00969-w

Ref. 467. Subbiah V, et al. (2024) CA Cancer J Clin, 74: 433. Available from: https://doi.org/10.3322/caac.21844

Ref. 468. Marret G, et al. (2025) Cancer Cell, 43: 597. Available from: https://doi.org/10.1016/j.ccell.2025.02.019

Ref. 469. Subbiah V, et al. (2025) Am Soc Clin Oncol Educ Book, 45: e100051. Available from: https://doi.org/10.1200/EDBK-25-100051

Ref. 470. US Food and Drug Administration. Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases. Accessed: June 30, 2025. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases

Ref. 471. Orcutt X, et al. (2025) Nat Med, 31: 457. Available from: https://doi.org/10.1038/s41591-024-03352-5

Ref. 472. Gueguen L, et al. (2025) NPJ Precis Oncol, 9: 28. Available from: https://doi.org/10.1038/s41698-025-00806-y

Ref. 473. Bickell NA, et al. (2024) JAMIA Open, 7: ooae131. Available from: https://doi.org/10.1093/jamiaopen/ooae131

Ref. 474. Katsoulakis E, et al. (2024) NPJ Digit Med, 7: 77. Available from: https://doi.org/10.1038/s41746-024-01073-0

Ref. 475. Unger JM, et al. (2024) J Clin Oncol, 42: 2139. Available from: https://doi.org/10.1200/JCO.23.01030

Ref. 476. National Academies of Sciences, Engineering, and Medicine. Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. Accessed: June 25, 2025. Available from: https://nap.nationalacademies.org/catalog/26479/improving-representation-in-clinical-trials-and-research-building-research-equity

Ref. 477. US Food and Drug Administration. Drug Trials Snapshots: VYLOY. Accessed: June 30, 2025. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vyloy

Ref. 478. Centers for Disease Control and Prevention. United States Cancer Cases and Death Statistics At a Glance. Accessed: June 30, 2025. Available from: https://gis.cdc.gov/Cancer/USCS/#/Demographics/

Ref. 479. US Food and Drug Administration. Drugs Trials Snapshot: ITOVEBI. Accessed: June 30, 2025. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drugs-trials-snapshot-itovebi

Ref. 480. Sekar RR, et al. (2025) J Natl Cancer Inst. Available from: https://doi.org/10.1093/jnci/djaf047

Ref. 481. Kirkwood MK, et al. (2025) JCO Oncol Pract, 21: 427. Available from: https://doi.org/10.1200/OP.24.00261

Ref. 482. Monroe C, et al. (2025) Pediatr Blood Cancer, 72: e31641. Available from: https://doi.org/10.1002/pbc.31641

Ref. 483. Boland MR, et al. (2024) JAMA Netw Open, 7: e2447635. Available from: https://doi.org/10.1001/jamanetworkopen.2024.47635

Ref. 484. Gopishetty S, et al. (2020) Am J Transl Res, 12: 5977. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7540092/

Ref. 485. American Association for Cancer Research. AACR Cancer Disparities Progress Report 2022. Accessed: June 30, 2025. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2022/06/AACR_CDPR_2022.pdf

Ref. 486. Kahn JM, et al. (2022) Cancer, 128: 216. Available from: https://doi.org/10.1002/cncr.33905

Ref. 487. Fashoyin-Aje LA, et al. (2024) JAMA Oncol, 10: 380. Available from: https://doi.org/10.1001/jamaoncol.2023.5781

Ref. 488. Faulk KE, et al. (2020) PLoS One, 15: e0230824. Available from: https://doi.org/10.1371/journal.pone.0230824

Ref. 489. US Food and Drug Administration. Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. Accessed: Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies

Ref. 490. American Association for Cancer Research. AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care. Accessed: June 30, 2025. Available from: https://www.aacr.org/professionals/research/aacr-covid-19-and-cancer-report-2022/

Ref. 491. Aiyegbusi OL, et al. (2024) Nat Med, 30: 3075. Available from: https://doi.org/10.1038/s41591-024-03323-w

Ref. 492. Jillella AP, et al. (2025) JAMA Oncol, 11: 400. Available from: https://doi.org/10.1001/jamaoncol.2024.7033

Ref. 493. Vanderpool RC, et al. (2024) J Natl Cancer Inst Monogr, 2024: 51. Available from: https://doi.org/10.1093/jncimonographs/lgae016

Ref. 494. Bloomberg New Economy International Cancer C, et al. (2024) Cancer Discov, 14: 2317. Available from: https://doi.org/10.1158/2159-8290.CD-24-1288

Ref. 495. Izarn F, et al. (2025) ESMO Open, 10: 104086. Available from: https://doi.org/10.1016/j.esmoop.2024.104086

Ref. 496. Taha T, et al. (2025) JAMA Oncol, 11: 668. Available from: https://doi.org/10.1001/jamaoncol.2025.0764

Ref. 497. Global Oncology Trends 2025. Accessed: June 11, 2025. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025

Ref. 498. Mehta GU, et al. (2024) N Engl J Med. Available from: https://doi.org/10.1056/NEJMp2409392

Ref. 499. World Health Organization. Guidance for Best Practices for Clinical Trials. Accessed: June 30, 2025. Available from: https://iris.who.int/bitstream/handle/10665/378782/9789240097711-eng.pdf

Ref. 500. Hamdy FC, et al. (2023) N Engl J Med, 388: 1547. Available from: https://doi.org/10.1056/NEJMoa2214122

Ref. 501. Newcomb LF, et al. (2024) JAMA, 331: 2084. Available from: https://doi.org/10.1001/jama.2024.6695

Ref. 502. Ajjawi I, et al. (2024) JAMA, 332: 2033. Available from: https://doi.org/10.1001/jama.2024.20580

Ref. 503. Diven MA, et al. (2024) JAMA Netw Open, 7: e2429760. Available from: https://doi.org/10.1001/jamanetworkopen.2024.29760

Ref. 504. Monda SM, et al. (2025) JAMA Oncol. Available from: https://doi.org/10.1001/jamaoncol.2025.0963

Ref. 505. Levyn H, et al. (2024) JAMA Otolaryngol Head Neck Surg. Available from: https://doi.org/10.1001/jamaoto.2024.1699

Ref. 506. Partridge AH, et al. (2025) JAMA Oncol, 11: 300. Available from: https://doi.org/10.1001/jamaoncol.2024.6556

Ref. 507. Lawrence W. History of Surgical Oncology. In: Norton JA, Barie PS, Bollinger RR, Chang AE, Lowry SF, Mulvihill SJ, et al., editors. Surgery. New York, NY: Springer New York; 2008. p 1889.

Ref. 508. Gianfaldoni S, et al. (2017) Open Access Maced J Med Sci, 5: 521. Available from: https://doi.org/10.3889/oamjms.2017.122

Ref. 509. DeVita VT, Jr., et al. (2008) Cancer Res, 68: 8643. Available from: https://doi.org/10.1158/0008-5472.CAN-07-6611

Ref. 510. Dobashi Y, et al. (2012) Chemotherapy, 1: 2.

Ref. 511. Zhang Y, et al. (2020) Cell Mol Immunol, 17: 807. Available from: https://doi.org/10.1038/s41423-020-0488-6

Ref. 512. US Food & Drug Administration. Oncology (Cancer) /Hematologic Malignancies Approval Notifications. Accessed: June 14, 2025. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications

Ref. 513. Tfayli AH, et al. (2025) Cancer, 131: e35590. Available from: https://doi.org/10.1002/cncr.35590

Ref. 514. Cherny NI, et al. (2025) Ann Oncol, 36: 247. Available from: https://doi.org/10.1016/j.annonc.2024.12.005

Ref. 515. Kim RB, et al. (2024) J Racial Ethn Health Disparities, 00: 10.1007/s40615. Available from: https://doi.org/10.1007/s40615-024-02077-y

Ref. 516. Tamirisa N, et al. (2023) Ann Surg: 00. Available from: https://doi.org/10.1097/SLA.0000000000006177

Ref. 517. Hooda Z, et al. (2025) Ann Thorac Surg. Available from: https://doi.org/10.1016/j.athoracsur.2025.03.042

Ref. 518. Lyons JM, et al. (2025) Cancers (Basel), 17. Available from: https://doi.org/10.3390/cancers17020207

Ref. 519. Dhruva SS, et al. (2024) Health Aff (Millwood), 43: 27. Available from: https://doi.org/10.1377/hlthaff.2023.00466

Ref. 520. Bhadouriya R, et al. (2025) Annals of Surgical Oncology, 32: 4034. Available from: https://doi.org/10.1245/s10434-025-17152-9

Ref. 521. Jackson I, et al. (2025) JCO Oncol Pract: OP2400871. Available from: https://doi.org/10.1200/OP-24-00871

Ref. 522. Grewal M, et al. (2025) World J Surg, 49: 262. Available from: https://doi.org/10.1002/wjs.12431

Ref. 523. Podany EL, et al. (2025) JAMA Netw Open, 8: e2461899. Available from: https://doi.org/10.1001/jamanetworkopen.2024.61899

Ref. 524. Chan K, et al. (2025) JAMA Oncol. Available from: https://doi.org/10.1001/jamaoncol.2025.1138

Ref. 525. Burotto M, et al. (2019) Semin Oncol, 46: 83. Available from: https://doi.org/10.1053/j.seminoncol.2019.01.002

Ref. 526. Topal H, et al. (2022) JAMA Netw Open, 5: e2248147. Available from: https://doi.org/10.1001/jamanetworkopen.2022.48147

Ref. 527. Son SY, et al. (2022) JAMA Surg, 157: 879. Available from: https://doi.org/10.1001/jamasurg.2022.2749

Ref. 528. Di Benedetto F, et al. (2023) JAMA Surg, 158: 46. Available from: https://doi.org/10.1001/jamasurg.2022.5697

Ref. 529. Bartels SAL, et al. (2023) Journal of Clinical Oncology, 41: 2159. Available from: https://doi.org/10.1200/Jco.22.01565

Ref. 530. Habermann EB, et al. (2025) J Am Coll Surg, 240: 95. Available from: https://doi.org/10.1097/XCS.0000000000001214

Ref. 531. van der Wilk BJ, et al. (2025) Lancet Oncol, 26: 425. Available from: https://doi.org/10.1016/S1470-2045(25)00027-0

Ref. 532. Kuerer HM, et al. (2025) JAMA Oncol, 11: 529. Available from: https://doi.org/10.1001/jamaoncol.2025.0207

Ref. 533. Cercek A, et al. (2025) N Engl J Med, 392: 2297. Available from: https://doi.org/10.1056/NEJMoa2404512

Ref. 534. McCrorie AD, et al. (2025) NPJ Breast Cancer, 11: 32. Available from: https://doi.org/10.1038/s41523-025-00744-9

Ref. 535. Gentilini OD, et al. (2023) JAMA Oncol, 9: 1557. Available from: https://doi.org/10.1001/jamaoncol.2023.3759

Ref. 536. Montagna G, et al. (2024) JAMA Oncol. Available from: https://doi.org/10.1001/jamaoncol.2024.0578

Ref. 537. Lerner SP, et al. (2024) N Engl J Med, 391: 1206. Available from: https://doi.org/10.1056/NEJMoa2401497

Ref. 538. van der Lei S, et al. (2025) Lancet Oncol, 26: 187. Available from: https://doi.org/10.1016/S1470-2045(24)00660-0

Ref. 539. Reyngold M, et al. (2025) JAMA Oncol, 11: 609. Available from: https://doi.org/10.1001/jamaoncol.2025.0460

Ref. 540. Feng QY, et al. (2025) Jama-Journal of the American Medical Association. Available from: https://doi.org/10.1001/jama.2025.8123

Ref. 541. Kanbergs A, et al. (2025) JAMA Netw Open, 8: e2453604. Available from: https://doi.org/10.1001/jamanetworkopen.2024.53604

Ref. 542. Abdel-Wahab M, et al. (2024) Lancet Oncol, 25: e545. Available from: https://doi.org/10.1016/S1470-2045(24)00407-8

Ref. 543. Wang K, et al. (2021) CA Cancer J Clin, 71: 437. Available from: https://doi.org/10.3322/caac.21689

Ref. 544. Kishan AU, et al. (2025) Clin Cancer Res, 31: 2530. Available from: https://doi.org/10.1158/1078-0432.CCR-24-3951

Ref. 545. Meattini I, et al. (2025) JAMA Oncol, 11: 329. Available from: https://doi.org/10.1001/jamaoncol.2024.5780

Ref. 546. Dix DB, et al. (2018) J Clin Oncol, 36: 1564. Available from: https://doi.org/10.1200/JCO.2017.77.1931

Ref. 547. Jagsi R, et al. (2024) J Clin Oncol, 42: 390. Available from: https://doi.org/10.1200/JCO.23.02270

Ref. 548. Whelan TJ, et al. (2023) N Engl J Med, 389: 612. Available from: https://doi.org/10.1056/NEJMoa2302344

Ref. 549. Mann GB, et al. (2024) Lancet, 403: 261. Available from: https://doi.org/10.1016/S0140-6736(23)02476-5

Ref. 550. Williams LJ, et al. (2024) Lancet Oncol, 25: 1213. Available from: https://doi.org/10.1016/S1470-2045(24)00347-4

Ref. 551. Chun SG, et al. (2024) JAMA Oncol, 10: 1111. Available from: https://doi.org/10.1001/jamaoncol.2024.1841

Ref. 552. van As N, et al. (2024) N Engl J Med, 391: 1413. Available from: https://doi.org/10.1056/NEJMoa2403365

Ref. 553. van Moorselaar RJA, et al. (2022) Eur Urol Open Sci, 35: 70. Available from: https://doi.org/10.1016/j.euros.2021.11.004

Ref. 554. Palma DA, et al. (2020) J Clin Oncol, 38: 2830. Available from: https://doi.org/10.1200/JCO.20.00818

Ref. 555. Donovan EK, et al. (2024) JAMA Oncol, 00: e241796. Available from: https://doi.org/10.1001/jamaoncol.2024.1796

Ref. 556. Chinniah S, et al. (2022) Int J Radiat Oncol Biol Phys, 114: 684. Available from: https://doi.org/10.1016/j.ijrobp.2022.07.014

Ref. 557. Mansouri A, et al. (2025) Nat Rev Clin Oncol, 22: 327. Available from: https://doi.org/10.1038/s41571-025-01013-1

Ref. 558. Cho WK, et al. (2024) JAMA Oncol, 10: 737. Available from: https://doi.org/10.1001/jamaoncol.2024.0565

Ref. 559. Lee SF, et al. (2024) BMJ, 386: e079089. Available from: https://doi.org/10.1136/bmj-2023-079089

Ref. 560. Booth S, et al. (2024) Pract Radiat Oncol, 14: e305. Available from: https://doi.org/10.1016/j.prro.2024.04.010

Ref. 561. American Association for Cancer Research. AACR Cancer Progress Report 2018. Accessed: June 30, 2025. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2020/09/AACR_CPR_2018.pdf

Ref. 562. Giugliano F, et al. (2025) Cancer Treat Rev, 136: 102940. Available from: https://doi.org/10.1016/j.ctrv.2025.102940

Ref. 563. Davis RA, et al. (2023) J Med Chem, 66: 9842. Available from: https://doi.org/10.1021/acs.jmedchem.3c00631

Ref. 564. Ganguly T, et al. (2023) J Nucl Med, 64: 639. Available from: https://doi.org/10.2967/jnumed.122.264749

Ref. 565. Merrell KW, et al. (2024) International Journal of Radiation OncologyBiologyPhysics, 120: S11. Available from: https://doi.org/10.1016/j.ijrobp.2024.07.003

Ref. 566. To J, et al. (2025) Nat Rev Drug Discov. Available from: https://doi.org/10.1038/d41573-025-00096-w

Ref. 567. Matikas A, et al. (2024) J Clin Oncol, 42: 3077. Available from: https://doi.org/10.1200/JCO.24.00178

Ref. 568. Patel SH, et al. (2025) Cancer, 131: e35759. Available from: https://doi.org/10.1002/cncr.35759

Ref. 569. Pautier P, et al. (2024) N Engl J Med, 391: 789. Available from: https://doi.org/10.1056/NEJMoa2403394

Ref. 570. Ye H, et al. (2024) JAMA, 332: 1634. Available from: https://doi.org/10.1001/jama.2024.19981

Ref. 571. Gilbert A, et al. (2025) Lancet Oncol, 26: 707. Available from: https://doi.org/10.1016/S1470-2045(25)00213-X

Ref. 572. US Food and Drug Administration. Safety announcement: FDA highlights importance of DPD deficiency discussions with patients prior to capecitabine or 5FU treatment. Accessed: June 25, 2025. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/safety-announcement-fda-highlights-importance-dpd-deficiency-discussions-patients-prior-capecitabine

Ref. 573. Gottschalk Z, et al. (2024) Curr Oncol Rep, 26: 959. Available from: https://doi.org/10.1007/s11912-024-01565-y

Ref. 574. Kasi PM, et al. (2024) Journal of Clinical Oncology, 42: 9. Available from: https://doi.org/10.1200/JCO.2024.42.3_suppl.9

Ref. 575. Heath E, et al. (2024) Cancer Res Commun, 4: 2598. Available from: https://doi.org/10.1158/2767-9764.CRC-24-0321

Ref. 576. Hage Chehade C, et al. (2024) JAMA Netw Open, 7: e2423186. Available from: https://doi.org/10.1001/jamanetworkopen.2024.23186

Ref. 577. Sengupta R, et al. (2019) Clin Cancer Res, 25: 5431. Available from: https://doi.org/10.1158/1078-0432.CCR-19-2655

Ref. 578. National Cancer Institite. Definition of HER2 – NCI Dictionary of Cancer Terms. Accessed: June 30, 2025. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/her2

Ref. 579. Arteaga CL, et al. (2014) Clin Cancer Res, 20: S1. Available from: https://doi.org/10.1158/1078-0432.CCR-14-2123

Ref. 580. Turner NC, et al. (2023) N Engl J Med, 388: 2058. Available from: https://doi.org/10.1056/NEJMoa2214131

Ref. 581. Turner NC, et al. (2024) N Engl J Med, 391: 1584. Available from: https://doi.org/10.1056/NEJMoa2404625

Ref. 582. Mullard A (2024) Nat Rev Drug Discov, 23: 885. Available from: https://doi.org/10.1038/d41573-024-00176-3

Ref. 583. Cho BC, et al. (2024) N Engl J Med, 391: 1486. Available from: https://doi.org/10.1056/NEJMoa2403614

Ref. 584. Horn L, et al. (2021) JAMA Oncol, 7: 1617. Available from: https://doi.org/10.1001/jamaoncol.2021.3523

Ref. 585. Peng L, et al. (2022) Front Oncol, 12: 863461. Available from: https://doi.org/10.3389/fonc.2022.863461

Ref. 586. Schram AM, et al. (2025) N Engl J Med, 392: 566. Available from: https://doi.org/10.1056/NEJMoa2405008

Ref. 587. Perol M, et al. (2025) J Clin Oncol, 43: 1920. Available from: https://doi.org/10.1200/JCO-25-00275

Ref. 588. Scott JA, et al. (2024) JCO Oncology Practice, 20: 145. Available from: https://doi.org/10.1200/op.22.00611

Ref. 589. Baron JM, et al. (2024) JCO Precis Oncol, 8: e2400039. Available from: https://doi.org/10.1200/PO.24.00039

Ref. 590. Roberts TJ, et al. (2023) JAMA Netw Open, 6: e2310809. Available from: https://doi.org/10.1001/jamanetworkopen.2023.10809

Ref. 591. Lemmon CA, et al. (2023) JCO Precis Oncol, 7: e2200294. Available from: https://doi.org/10.1200/PO.22.00294

Ref. 592. Sengupta R, et al. (2020) Clin Cancer Res, 26: 5055. Available from: https://doi.org/10.1158/1078-0432.CCR-20-3187

Ref. 593. Bardia A, et al. (2025) J Clin Oncol, 43: 285. Available from: https://doi.org/10.1200/JCO.24.00920

Ref. 594. Schmid P, et al. (2025) Ther Adv Med Oncol, 17: 17588359251327992. Available from: https://doi.org/10.1177/17588359251327992

Ref. 595. Shatsky RA, et al. (2024) Nat Med, 30: 3737. Available from: https://doi.org/10.1038/s41591-024-03267-1

Ref. 596. Sands J, et al. (2025) J Clin Oncol, 43: 1254. Available from: https://doi.org/10.1200/JCO-24-01349

Ref. 597. US Food and Drug Administration. FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer. Accessed: June 30, 2025. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer

Ref. 598. Camidge DR, et al. (2024) J Clin Oncol, 42: 3000. Available from: https://doi.org/10.1200/JCO.24.00720

Ref. 599. Grisham R, et al. (2025) Int J Gynecol Cancer. Available from: https://doi.org/10.1136/ijgc-2024-005919

Ref. 600. McNamara B, et al. (2024) Gynecol Oncol, 183: 133. Available from: https://doi.org/10.1016/j.ygyno.2024.01.028

Ref. 601. Mullard A (2025) Nat Rev Drug Discov, 24: 408. Available from: https://doi.org/10.1038/d41573-025-00086-y

Ref. 602. Elmadani M, et al. (2025) Cancers (Basel), 17. Available from: https://doi.org/10.3390/cancers17101721

Ref. 603. Smith SM, et al. Clinical Cancer Advances 2021: ASCO’s Report on Progress Against Cancer. Journal of Clinical Oncology2021. p JCO.20.03420Available from: https://ascopubs.org/doi/10.1200/JCO.20.03420

Ref. 604. Gelderblom H, et al. (2024) Lancet, 403: 2709. Available from: https://doi.org/10.1016/S0140-6736(24)00885-7

Ref. 605. Harding JJ, et al. (2023) Lancet Oncol, 24: 772. Available from: https://doi.org/10.1016/S1470-2045(23)00242-5

Ref. 606. Yan H, et al. (2009) N Engl J Med, 360: 765. Available from: https://doi.org/10.1056/NEJMoa0808710

Ref. 607. Dang L, et al. (2009) Nature, 462: 739. Available from: https://doi.org/10.1038/nature08617

Ref. 608. Duncan CG, et al. (2012) Genome Res, 22: 2339. Available from: https://doi.org/10.1101/gr.132738.111

Ref. 609. Koivunen P, et al. (2012) Nature, 483: 484. Available from: https://doi.org/10.1038/nature10898

Ref. 610. Turcan S, et al. (2012) Nature, 483: 479. Available from: https://doi.org/10.1038/nature10866

Ref. 611. Mellinghoff IK, et al. (2023) Nat Med, 29: 615. Available from: https://doi.org/10.1038/s41591-022-02141-2

Ref. 612. Moertel CL, et al. (2025) J Clin Oncol, 43: 716. Available from: https://doi.org/10.1200/JCO.24.01034

Ref. 613. Hiam-Galvez KJ, et al. (2021) Nat Rev Cancer, 21: 345. Available from: https://doi.org/10.1038/s41568-021-00347-z

Ref. 614. Mishra AK, et al. (2022) Diseases, 10: 60. Available from: https://doi.org/10.3390/diseases10030060

Ref. 615. Kaufmann SHE (2019) Front Immunol, 10: 684. Available from: https://doi.org/10.3389/fimmu.2019.00684

Ref. 616. Marin-Acevedo JA, et al. (2021) J Hematol Oncol, 14: 45. Available from: https://doi.org/10.1186/s13045-021-01056-8

Ref. 617. Garon EB, et al. (2019) Journal of Clinical Oncology, 37: 2518. Available from: https://doi.org/10.1200/Jco.19.00934

Ref. 618. Wolchok JD, et al. (2025) N Engl J Med, 392: 11. Available from: https://doi.org/10.1056/NEJMoa2407417

Ref. 619. Long GV, et al. (2025) J Clin Oncol, 43: 938. Available from: https://doi.org/10.1200/JCO.24.00400

Ref. 620. Clingan P, et al. (2023) J Immunother Cancer, 11. Available from: https://doi.org/10.1136/jitc-2023-007637

Ref. 621. Roy Chattopadhyay N, et al. (2017) Drug Discov Ther, 11: 170. Available from: https://doi.org/10.5582/ddt.2017.01030

Ref. 622. Hu C, et al. (2025) Cancer Research, 85: CT011. Available from: https://doi.org/10.1158/1538-7445.Am2025-ct011

Ref. 623. Chen X, et al. (2024) Signal Transduct Target Ther, 9: 148. Available from: https://doi.org/10.1038/s41392-024-01865-6

Ref. 624. Haslam A, et al. (2025) Int J Cancer, 156: 2352. Available from: https://doi.org/10.1002/ijc.35347

Ref. 625. Jayathilaka B, et al. (2025) Br J Cancer, 132: 51. Available from: https://doi.org/10.1038/s41416-024-02887-1

Ref. 626. Nielsen DL, et al. (2024) JAMA Oncol, 10: 1390. Available from: https://doi.org/10.1001/jamaoncol.2024.3065

Ref. 627. Ruiz-Esteves KN, et al. (2024) JAMA Oncol, 10: 1409. Available from: https://doi.org/10.1001/jamaoncol.2024.3104

Ref. 628. Eochagain CM, et al. (2025) Lancet Oncol, 26: e90. Available from: https://doi.org/10.1016/S1470-2045(24)00404-2

Ref. 629. Kao C, et al. (2025) Nat Commun, 16: 3531. Available from: https://doi.org/10.1038/s41467-025-58512-z

Ref. 630. Alban TJ, et al. (2024) Nat Med, 30: 3209. Available from: https://doi.org/10.1038/s41591-024-03240-y

Ref. 631. Campbell MJ, et al. (2024) Cell Rep Med, 5: 101799. Available from: https://doi.org/10.1016/j.xcrm.2024.101799

Ref. 632. Hernando-Calvo A, et al. (2024) JCO Precis Oncol, 8: e2400100. Available from: https://doi.org/10.1200/PO.24.00100

Ref. 633. Usset J, et al. (2024) Nat Genet, 56: 2112. Available from: https://doi.org/10.1038/s41588-024-01899-0

Ref. 634. Yan Y, et al. (2025) Nat Genet, 57: 126. Available from: https://doi.org/10.1038/s41588-024-01998-y

Ref. 635. Hamidi H, et al. (2024) Cancer Cell, 42: 2098. Available from: https://doi.org/10.1016/j.ccell.2024.10.016

Ref. 636. Patkar S, et al. (2024) NPJ Precis Oncol, 8: 280. Available from: https://doi.org/10.1038/s41698-024-00765-w

Ref. 637. Rakaee M, et al. (2025) JAMA Oncol, 11: 109. Available from: https://doi.org/10.1001/jamaoncol.2024.5356

Ref. 638. Yoo SK, et al. (2025) Nat Med, 31: 869. Available from: https://doi.org/10.1038/s41591-024-03398-5

Ref. 639. Lin Y, et al. (2025) Med, 6: 100530. Available from: https://doi.org/10.1016/j.medj.2024.10.007

Ref. 640. Park JS, et al. (2023) Nature, 617: 377. Available from: https://doi.org/10.1038/s41586-023-06026-3

Ref. 641. Rosario SR, et al. (2024) Nat Commun, 15: 10609. Available from: https://doi.org/10.1038/s41467-024-54565-8

Ref. 642. Gadina M, et al. (2024) Science, 384: 1303. Available from: https://doi.org/10.1126/science.adq1717

Ref. 643. Kudo M, et al. (2025) Lancet, 405: 203. Available from: https://doi.org/10.1016/S0140-6736(24)02575-3

Ref. 644. Sangro B, et al. (2025) Lancet, 405: 216. Available from: https://doi.org/10.1016/S0140-6736(24)02551-0

Ref. 645. Awada G, et al. (2025) Nat Cancer, 6: 967. Available from: https://doi.org/10.1038/s43018-025-00990-7

Ref. 646. Uppaluri R, et al. (2025) Cancer Research, 85: CT001. Available from: https://doi.org/10.1158/1538-7445.Am2025-ct001

Ref. 647. Rohaan MW, et al. (2019) Virchows Arch, 474: 449. Available from: https://doi.org/10.1007/s00428-018-2484-0

Ref. 648. Mulvey A, et al. (2025) Nat Rev Drug Discov, 24: 379. Available from: https://doi.org/10.1038/s41573-024-01100-5

Ref. 649. Bagley SJ, et al. (2025) Nat Med. Available from: https://doi.org/10.1038/s41591-025-03745-0

Ref. 650. Choi BD, et al. (2024) N Engl J Med, 390: 1290. Available from: https://doi.org/10.1056/NEJMoa2314390

Ref. 651. Li CH, et al. (2025) Nat Med, 31: 1125. Available from: https://doi.org/10.1038/s41591-025-03513-0

Ref. 652. Qi C, et al. (2025) Lancet, 405: 2049. Available from: https://doi.org/10.1016/S0140-6736(25)00860-8

Ref. 653. Reiss KA, et al. (2025) Nat Med, 31: 1171. Available from: https://doi.org/10.1038/s41591-025-03495-z

Ref. 654. Monje M, et al. (2025) Nature, 637: 708. Available from: https://doi.org/10.1038/s41586-024-08171-9

Ref. 655. D’Angelo SP, et al. (2024) Lancet, 403: 1460. Available from: https://doi.org/10.1016/S0140-6736(24)00319-2

Ref. 656. Baselga J, et al. (2015) Clin Cancer Res, 21: S1. Available from: https://doi.org/10.1158/1078-0432.CCR-15-1846

Ref. 657. Tian Z, et al. (2021) J Hematol Oncol, 14: 75. Available from: https://doi.org/10.1186/s13045-021-01084-4

Ref. 658. Rolin C, et al. (2024) Cell Mol Immunol, 21: 643. Available from: https://doi.org/10.1038/s41423-024-01176-4

Ref. 659. Zahavi D, et al. (2018) Antib Ther, 1: 7. Available from: https://doi.org/10.1093/abt/tby002

Ref. 660. Shitara K, et al. (2023) Lancet, 401: 1655. Available from: https://doi.org/10.1016/S0140-6736(23)00620-7

Ref. 661. Alaggio R, et al. (2022) Leukemia, 36: 1720. Available from: https://doi.org/10.1038/s41375-022-01620-2

Ref. 662. Cerhan JR, et al. (2024) Am J Hematol, 99: 408. Available from: https://doi.org/10.1002/ajh.27202

Ref. 663. Zhu DT, et al. (2024) Sci Rep, 14: 14564. Available from: https://doi.org/10.1038/s41598-024-65590-4

Ref. 664. Zhang N, et al. (2023) Blood Cancer J, 13: 82. Available from: https://doi.org/10.1038/s41408-023-00853-3

Ref. 665. Huang L, et al. (2024) Cancer Med, 13: e70224. Available from: https://doi.org/10.1002/cam4.70224

Ref. 666. Wang S, et al. (2025) BMC Public Health, 25: 1223. Available from: https://doi.org/10.1186/s12889-025-22376-1

Ref. 667. Xie J, et al. (2025) Front Pediatr, 13: 1618810. Available from: https://doi.org/10.3389/fped.2025.1618810

Ref. 668. Flowers CR, et al. (2025) Blood Cancer Discov, 6: 79. Available from: https://doi.org/10.1158/2643-3230.BCD-24-0153

Ref. 669. Miranda-Galvis M, et al. (2023) Blood Adv, 7: 6466. Available from: https://doi.org/10.1182/bloodadvances.2023010690

Ref. 670. Doddi S, et al. (2024) Cancer Diagn Progn, 4: 288. Available from: https://doi.org/10.21873/cdp.10322

Ref. 671. Prissel CM, et al. (2025) Mayo Clin Proc. Available from: https://doi.org/10.1016/j.mayocp.2024.11.026

Ref. 672. Fei-Zhang DJ, et al. (2025) Blood Adv, 9: 1463. Available from: https://doi.org/10.1182/bloodadvances.2024013956

Ref. 673. Newman H, et al. (2025) Blood Cancer Discov. Available from: https://doi.org/10.1158/2643-3230.BCD-25-0049

Ref. 674. Corrigan KL, et al. (2025) Cancer Epidemiol Biomarkers Prev. Available from: https://doi.org/10.1158/1055-9965.EPI-25-0049

Ref. 675. Loeb N, et al. (2025) Blood Neoplasia, 2: 100070. Available from: https://doi.org/10.1016/j.bneo.2025.100070

Ref. 676. Valtis YK, et al. (2025) JAMA Oncol. Available from: https://doi.org/10.1001/jamaoncol.2025.1127

Ref. 677. Fiala MA, et al. (2025) Clin Lymphoma Myeloma Leuk, 25: 109. Available from: https://doi.org/10.1016/j.clml.2024.07.017

Ref. 678. Hsieh TC, et al. (2025) Am J Hosp Palliat Care, 42: 236. Available from: https://doi.org/10.1177/10499091241254523

Ref. 679. de Smith AJ, et al. (2024) Cell Genom: 100526. Available from: https://doi.org/10.1016/j.xgen.2024.100526

Ref. 680. Churchman ML, et al. (2018) Cancer Cell, 33: 937. Available from: https://doi.org/10.1016/j.ccell.2018.03.021

Ref. 681. de Smith AJ, et al. (2023) Front Oncol, 13: 1299355. Available from: https://doi.org/10.3389/fonc.2023.1299355

Ref. 682. Lee MJ, et al. (2020) Cancer, 126: 3493. Available from: https://doi.org/10.1002/cncr.32866

Ref. 683. Peres LC, et al. (2022) Blood Adv, 6: 3767. Available from: https://doi.org/10.1182/bloodadvances.2021006652

Ref. 684. Dong J, et al. (2022) Blood Cancer J, 12: 34. Available from: https://doi.org/10.1038/s41408-022-00633-5

Ref. 685. Fernandez-Maestre I, et al. (2024) Blood Cancer Discov, 5: 377. Available from: https://doi.org/10.1158/2643-3230.BCD-24-0009

Ref. 686. Hogg G, et al. (2023) Cancer Genet, 278-279: 38. Available from: https://doi.org/10.1016/j.cancergen.2023.07.006

Ref. 687. Lachowiez CA, et al. (2025) Blood Cancer Discov. Available from: https://doi.org/10.1158/2643-3230.BCD-24-0256

Ref. 688. Huang G, et al. (2025) Ann Hematol, 104: 1399. Available from: https://doi.org/10.1007/s00277-024-05885-8

Ref. 689. Meyer SE, et al. (2016) Cancer Discov, 6: 501. Available from: https://doi.org/10.1158/2159-8290.CD-16-0008

Ref. 690. Wozniak M, et al. (2025) Ther Adv Med Oncol, 17: 17588359241306026. Available from: https://doi.org/10.1177/17588359241306026

Ref. 691. Khouri MR, et al. (2025) Cancer, 131: e35846. Available from: https://doi.org/10.1002/cncr.35846

Ref. 692. Zoller J, et al. (2023) Front Oncol, 13: 1205855. Available from: https://doi.org/10.3389/fonc.2023.1205855

Ref. 693. Gong Y, et al. (2021) Oncol Rep, 45: 49. Available from: https://doi.org/10.3892/or.2020.7846

Ref. 694. Godley LA, et al. (2024) Am Soc Clin Oncol Educ Book, 44: e432218. Available from: https://doi.org/10.1200/EDBK_432218

Ref. 695. Mitelman F, et al. (2007) Nat Rev Cancer, 7: 233. Available from: https://doi.org/10.1038/nrc2091

Ref. 696. Rabbitts TH (1994) Nature, 372: 143. Available from: https://doi.org/10.1038/372143a0

Ref. 697. Gulla A, et al. (2021) Blood Cancer Discov, 2: 468. Available from: https://doi.org/10.1158/2643-3230.BCD-21-0047

Ref. 698. Senapati J, et al. (2023) Blood Cancer J, 13: 58. Available from: https://doi.org/10.1038/s41408-023-00823-9

Ref. 699. Jabbour E, et al. (2024) Am J Hematol, 99: 2191. Available from: https://doi.org/10.1002/ajh.27443

Ref. 700. Atallah E, et al. (2021) JAMA Oncol, 7: 42. Available from: https://doi.org/10.1001/jamaoncol.2020.5774

Ref. 701. Catalano F, et al. (2023) Cancers (Basel), 15. Available from: https://doi.org/10.3390/cancers15072074

Ref. 702. Venkataraman V, et al. (2023) Oncologist, 28: 671. Available from: https://doi.org/10.1093/oncolo/oyad167

Ref. 703. Barnett CM, et al. (2013) Hematol Oncol Clin North Am, 27: 871. Available from: https://doi.org/10.1016/j.hoc.2013.07.003

Ref. 704. Blay JY, et al. (2024) Lancet Oncol, 25: 1163. Available from: https://doi.org/10.1016/S1470-2045(24)00318-8

Ref. 705. Cohen P, et al. (2021) Nat Rev Drug Discov, 20: 551. Available from: https://doi.org/10.1038/s41573-021-00195-4

Ref. 706. Roskoski R, Jr. (2024) Pharmacol Res, 200: 107059. Available from: https://doi.org/10.1016/j.phrs.2024.107059

Ref. 707. Adashek JJ, et al. (2025) Med, 6: 100550. Available from: https://doi.org/10.1016/j.medj.2024.11.003

Ref. 708. Brown A, et al. (2024) Cancers (Basel), 16. Available from: https://doi.org/10.3390/cancers16050997

Ref. 709. Christyani G, et al. (2024) Int J Mol Sci, 25. Available from: https://doi.org/10.3390/ijms25021201

Ref. 710. Hyman DM, et al. (2015) N Engl J Med, 373: 726. Available from: https://doi.org/10.1056/NEJMoa1502309

Ref. 711. Subbiah V, et al. (2020) Cancer Discov, 10: 657. Available from: https://doi.org/10.1158/2159-8290.CD-19-1265

Ref. 712. Doke R, et al. (2025) Naunyn Schmiedebergs Arch Pharmacol, 398: 6407. Available from: https://doi.org/10.1007/s00210-024-03769-2

Ref. 713. Goyal G, et al. (2025) Blood, 145: 2100. Available from: https://doi.org/10.1182/blood.2024028032

Ref. 714. Kwon R, et al. (2024) Haematologica, 109: 379. Available from: https://doi.org/10.3324/haematol.2022.282442

Ref. 715. Cho YU (2024) Blood Res, 59: 11. Available from: https://doi.org/10.1007/s44313-024-00010-0

Ref. 716. Haferlach T (2020) Hematol Rep, 12: 8957. Available from: https://doi.org/10.4081/hr.2020.8957

Ref. 717. Boonbanjong P, et al. (2022) Biosensors (Basel), 12. Available from: https://doi.org/10.3390/bios12090677

Ref. 718. Ludwig KU, et al. (2021) Nat Biotechnol, 39: 1556. Available from: https://doi.org/10.1038/s41587-021-00966-9

Ref. 719. Dremsek P, et al. (2021) Genes (Basel), 12. Available from: https://doi.org/10.3390/genes12121958

Ref. 720. Yang X, et al. (2019) Int J Mol Sci, 20. Available from: https://doi.org/10.3390/ijms20184576

Ref. 721. Kuhn MWM, et al. (2025) Leukemia. Available from: https://doi.org/10.1038/s41375-025-02639-x

Ref. 722. Garcia-Sanz R, et al. (2021) Cancers (Basel), 13. Available from: https://doi.org/10.3390/cancers13071541

Ref. 723. Zeng AGX, et al. (2025) Blood Cancer Discov: OF1. Available from: https://doi.org/10.1158/2643-3230.BCD-24-0342

Ref. 724. Jayavel S, et al. (2025) J Egypt Natl Canc Inst, 37: 12. Available from: https://doi.org/10.1186/s43046-025-00263-5

Ref. 725. Tessmer MS, et al. (2017) Clin Cancer Res, 23: 5325. Available from: https://doi.org/10.1158/1078-0432.CCR-17-2302

Ref. 726. Erba HP, et al. (2023) Lancet, 401: 1571. Available from: https://doi.org/10.1016/S0140-6736(23)00464-6

Ref. 727. Dohner H, et al. (2022) Blood Adv, 6: 5345. Available from: https://doi.org/10.1182/bloodadvances.2022007223

Ref. 728. Abbas HA, et al. (2019) Cancer Manag Res, 11: 8817. Available from: https://doi.org/10.2147/CMAR.S177894

Ref. 729. Onate G, et al. (2023) Blood Cancer J, 13: 69. Available from: https://doi.org/10.1038/s41408-023-00839-1

Ref. 730. Gupta SV, et al. (2024) Princ Pract Clin Res, 10: 47. Available from: https://doi.org/10.21801/ppcrj.2024.102.7

Ref. 731. Waitkus MS, et al. (2018) Cancer Cell, 34: 186. Available from: https://doi.org/10.1016/j.ccell.2018.04.011

Ref. 732. Nassereddine S, et al. (2017) Ann Hematol, 96: 1983. Available from: https://doi.org/10.1007/s00277-017-3161-0

Ref. 733. Norman M, et al. (2024) Expert Rev Hematol, 17: 755. Available from: https://doi.org/10.1080/17474086.2024.2422554

Ref. 734. Carosi F, et al. (2024) Cancers (Basel), 16. Available from: https://doi.org/10.3390/cancers16152752

Ref. 735. Issa GC, et al. (2023) Nature, 615: 920. Available from: https://doi.org/10.1038/s41586-023-05812-3

Ref. 736. Issa GC, et al. (2025) J Clin Oncol, 43: 75. Available from: https://doi.org/10.1200/JCO.24.00826

Ref. 737. Issa GC, et al. (2021) Leukemia, 35: 2482. Available from: https://doi.org/10.1038/s41375-021-01309-y

Ref. 738. Garber K (2024) Nat Rev Drug Discov, 23: 567. Available from: https://doi.org/10.1038/d41573-024-00106-3

Ref. 739. Kantarjian H, et al. (2025) Am J Hematol, 100: 1205. Available from: https://doi.org/10.1002/ajh.27708

Ref. 740. Wang R, et al. (2025) J Hematol Oncol, 18: 51. Available from: https://doi.org/10.1186/s13045-025-01704-3

Ref. 741. Brown JR, et al. (2025) N Engl J Med, 392: 748. Available from: https://doi.org/10.1056/NEJMoa2409804

Ref. 742. Wang L, et al. (2020) Signal Transduct Target Ther, 5: 15. Available from: https://doi.org/10.1038/s41392-020-0113-2

Ref. 743. Crisci S, et al. (2019) Front Oncol, 9: 443. Available from: https://doi.org/10.3389/fonc.2019.00443

Ref. 744. Thomas CJ, et al. (2024) Cancers (Basel), 16. Available from: https://doi.org/10.3390/cancers16101937

Ref. 745. D’Alo F, et al. (2024) Cancers (Basel), 16. Available from: https://doi.org/10.3390/cancers16122243

Ref. 746. Pal Singh S, et al. (2018) Mol Cancer, 17: 57. Available from: https://doi.org/10.1186/s12943-018-0779-z

Ref. 747. Mehra S, et al. (2024) Int J Mol Sci, 25. Available from: https://doi.org/10.3390/ijms25147516

Ref. 748. Adams CM, et al. (2018) Front Oncol, 8: 636. Available from: https://doi.org/10.3389/fonc.2018.00636

Ref. 749. Ghione P, et al. (2024) Haematologica, 109: 2802. Available from: https://doi.org/10.3324/haematol.2022.282362

Ref. 750. Al Sbihi A, et al. (2024) Cancers (Basel), 16. Available from: https://doi.org/10.3390/cancers16040827

Ref. 751. Jain N, et al. (2023) J Hematol Oncol, 16: 99. Available from: https://doi.org/10.1186/s13045-023-01496-4

Ref. 752. Allen P, et al. (2025) Clin Lymphoma Myeloma Leuk. Available from: https://doi.org/10.1016/j.clml.2025.05.002

Ref. 753. Foss FM, et al. (2025) J Clin Oncol, 43: 1198. Available from: https://doi.org/10.1200/JCO-24-01549

Ref. 754. Jurczyszyn A, et al. (2025) Pol Arch Intern Med, 135. Available from: https://doi.org/10.20452/pamw.16994

Ref. 755. Lin CH, et al. (2024) Int J Mol Sci, 25. Available from: https://doi.org/10.3390/ijms25116192

Ref. 756. Sedlacek J (2025) Clin Exp Med, 25: 176. Available from: https://doi.org/10.1007/s10238-025-01713-z

Ref. 757. Fricker LD (2020) Annu Rev Pharmacol Toxicol, 60: 457. Available from: https://doi.org/10.1146/annurev-pharmtox-010919-023603

Ref. 758. Durie BGM, et al. (2017) Lancet, 389: 519. Available from: https://doi.org/10.1016/S0140-6736(16)31594-X

Ref. 759. Yin J, et al. (2024) Sci Rep, 14: 28557. Available from: https://doi.org/10.1038/s41598-024-79537-2

Ref. 760. Dana H, et al. (2021) Acta Pharm Sin B, 11: 1129. Available from: https://doi.org/10.1016/j.apsb.2020.10.020

Ref. 761. Laetsch TW, et al. (2023) Journal of Clinical Oncology, 41: 1664. Available from: https://doi.org/10.1200/Jco.22.00642

Ref. 762. Westin JR, et al. (2023) N Engl J Med, 389: 148. Available from: https://doi.org/10.1056/NEJMoa2301665

Ref. 763. Jagannath S, et al. (2025) J Clin Oncol: JCO2500760. Available from: https://doi.org/10.1200/JCO-25-00760

Ref. 764. Brudno JN, et al. (2024) JAMA, 332: 1924. Available from: https://doi.org/10.1001/jama.2024.19462

Ref. 765. Roddie C, et al. (2021) J Clin Oncol, 39: 3352. Available from: https://doi.org/10.1200/JCO.21.00917

Ref. 766. Roddie C, et al. (2024) N Engl J Med, 391: 2219. Available from: https://doi.org/10.1056/NEJMoa2406526

Ref. 767. Hamilton MP, et al. (2024) N Engl J Med, 390: 2047. Available from: https://doi.org/10.1056/NEJMoa2401361

Ref. 768. Elsallab M, et al. (2024) Blood, 143: 2099. Available from: https://doi.org/10.1182/blood.2024024166

Ref. 769. Tix T, et al. (2024) Clin Cancer Res, 30: 4690. Available from: https://doi.org/10.1158/1078-0432.CCR-24-1798

Ref. 770. Ghilardi G, et al. (2024) Nature Medicine, 30: 984. Available from: https://doi.org/10.1038/s41591-024-02826-w

Ref. 771. Chung A, et al. (2025) Blood Adv. Available from: https://doi.org/10.1182/bloodadvances.2024015634

Ref. 772. Byrne MT, et al. (2025) JAMA Oncol, 11: 481. Available from: https://doi.org/10.1001/jamaoncol.2025.0042

Ref. 773. US Food and Drug Administration. FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. Accessed: June 30, 2025. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor

Ref. 774. Medina-Olivares FJ, et al. (2024) Front Oncol, 14: 1397613. Available from: https://doi.org/10.3389/fonc.2024.1397613

Ref. 775. Atallah R, et al. (2025) JCO Glob Oncol, 11: e2400441. Available from: https://doi.org/10.1200/GO-24-00441

Ref. 776. Wellhausen N, et al. (2023) Sci Transl Med, 15: eadi1145. Available from: https://doi.org/10.1126/scitranslmed.adi1145

Ref. 777. Hunter TL, et al. (2025) Science, 388: 1311. Available from: https://doi.org/10.1126/science.ads8473

Ref. 778. Willyard C (2025) Nature, 641: 1090. Available from: https://doi.org/10.1038/d41586-025-01570-6

Ref. 779. Casirati G, et al. (2023) Nature, 621: 404. Available from: https://doi.org/10.1038/s41586-023-06496-5

Ref. 780. Rampotas A, et al. (2025) Bone Marrow Transplantation, 60: 6. Available from: https://doi.org/10.1038/s41409-024-02429-6

Ref. 781. Herrera AF, et al. (2024) N Engl J Med, 391: 1379. Available from: https://doi.org/10.1056/NEJMoa2405888

Ref. 782. Brown PA, et al. (2021) JAMA, 325: 833. Available from: https://doi.org/10.1001/jama.2021.0669

Ref. 783. Locatelli F, et al. (2021) JAMA, 325: 843. Available from: https://doi.org/10.1001/jama.2021.0987

Ref. 784. Kantarjian H, et al. (2017) N Engl J Med, 376: 836. Available from: https://doi.org/10.1056/NEJMoa1609783

Ref. 785. Litzow MR, et al. (2024) N Engl J Med, 391: 320. Available from: https://doi.org/10.1056/NEJMoa2312948

Ref. 786. van der Sluis IM, et al. (2023) N Engl J Med, 388: 1572. Available from: https://doi.org/10.1056/NEJMoa2214171

Ref. 787. Gupta S, et al. (2025) N Engl J Med, 392: 875. Available from: https://doi.org/10.1056/NEJMoa2411680

Ref. 788. Firestone R, et al. (2023) Blood Cancer Discov, 4: 433. Available from: https://doi.org/10.1158/2643-3230.BCD-23-0176

Ref. 789. Shouse G (2025) Blood Rev, 69: 101251. Available from: https://doi.org/10.1016/j.blre.2024.101251

Ref. 790. D’Souza A, et al. (2024) Blood, 144: 495. Available from: https://doi.org/10.1182/blood-2024-200181

Ref. 791. Lee H, et al. (2024) Blood, 143: 1211. Available from: https://doi.org/10.1182/blood.2023022499

Ref. 792. Cohen YC, et al. (2025) N Engl J Med, 392: 138. Available from: https://doi.org/10.1056/NEJMoa2406536

Ref. 793. Sehn LH, et al. (2025) Blood, 145: 708. Available from: https://doi.org/10.1182/blood.2024025454

Ref. 794. Thieblemont C, et al. (2024) Leukemia, 38: 2653. Available from: https://doi.org/10.1038/s41375-024-02410-8

Ref. 795. Dima D, et al. (2025) Blood Cancer J, 15: 111. Available from: https://doi.org/10.1038/s41408-025-01314-9

Ref. 796. Dimopoulos MA, et al. (2023) J Clin Oncol, 41: 1590. Available from: https://doi.org/10.1200/JCO.22.00940

Ref. 797. Sonneveld P, et al. (2023) J Clin Oncol, 41: 1600. Available from: https://doi.org/10.1200/JCO.21.02734

Ref. 798. Dimopoulos MA, et al. (2025) N Engl J Med, 392: 1777. Available from: https://doi.org/10.1056/NEJMoa2409029

Ref. 799. Sonneveld P, et al. (2024) N Engl J Med, 390: 301. Available from: https://doi.org/10.1056/NEJMoa2312054

Ref. 800. Facon T, et al. (2024) N Engl J Med, 391: 1597. Available from: https://doi.org/10.1056/NEJMoa2400712

Ref. 801. Perrot A, et al. (2025) Blood, 146: 52. Available from: https://doi.org/10.1182/blood.2024026230

Ref. 802. Alshammari F, et al. (2025) Hematology, 30: 2448898. Available from: https://doi.org/10.1080/16078454.2024.2448898

Ref. 803. Camacho-Arteaga L, et al. (2025) JAMA Netw Open, 8: e2461683. Available from: https://doi.org/10.1001/jamanetworkopen.2024.61683

Ref. 804. Bouchkouj N, et al. (2025) JAMA, 333: 1354. Available from: https://doi.org/10.1001/jama.2024.28312

Ref. 805. Nath K, et al. (2024) Blood Cancer J, 14: 88. Available from: https://doi.org/10.1038/s41408-024-01043-5

Ref. 806. Toret E, et al. (2021) Hum Vaccin Immunother, 17: 1132. Available from: https://doi.org/10.1080/21645515.2020.1802975

Ref. 807. Kamboj M, et al. (2024) JCO Oncol Pract, 20: 889. Available from: https://doi.org/10.1200/OP.24.00107

Ref. 808. Malard F, et al. (2021) Blood Cancer J, 11: 142. Available from: https://doi.org/10.1038/s41408-021-00534-z

Ref. 809. Murray J, et al. Graft-Versus-Host Disease (GvHD). In: Kenyon M, Babic A, editors. The European Blood and Marrow Transplantation Textbook for Nurses: Under the Auspices of EBMT. Cham (CH)2018. p 221. Available from: https://www.ncbi.nlm.nih.gov/books/NBK543657/

Ref. 810. Westerveld ASR, et al. (2024) Blood Cancer J, 14: 150. Available from: https://doi.org/10.1038/s41408-024-01122-7

Ref. 811. Rosenberg AS, et al. (2021) Blood Cancer J, 11: 5. Available from: https://doi.org/10.1038/s41408-020-00400-4

Ref. 812. Kumar V, et al. (2019) Blood Cancer J, 9: 75. Available from: https://doi.org/10.1038/s41408-019-0237-1

Ref. 813. Palfi S, et al. (2025) Blood Cancer J, 15: 63. Available from: https://doi.org/10.1038/s41408-025-01261-5

Ref. 814. Jabbour E, et al. (2025) JAMA, 333: 1618. Available from: https://doi.org/10.1001/jama.2025.0220

Ref. 815. El-Cheikh J, et al. (2023) Blood Cancer J, 13: 83. Available from: https://doi.org/10.1038/s41408-023-00849-z

Ref. 816. Geraghty AC, et al. (2025) Cell, 188: 3238. Available from: https://doi.org/10.1016/j.cell.2025.03.041

Ref. 817. Ho MH, et al. (2025) Support Care Cancer, 33: 312. Available from: https://doi.org/10.1007/s00520-025-09356-2

Ref. 818. Hshieh TT, et al. (2018) JAMA Oncol, 4: 686. Available from: https://doi.org/10.1001/jamaoncol.2017.5674

Ref. 819. Stefanski KJ, et al. (2021) J Natl Cancer Inst, 113: 481. Available from: https://doi.org/10.1093/jnci/djaa102

Ref. 820. Dai H, et al. (2025) Sci Rep, 15: 17763. Available from: https://doi.org/10.1038/s41598-025-02720-6

Ref. 821. Baum J, et al. (2023) Sci Rep, 13: 22856. Available from: https://doi.org/10.1038/s41598-023-50289-9

Ref. 822. Ouchveridze E, et al. (2022) Blood Cancer J, 12: 74. Available from: https://doi.org/10.1038/s41408-022-00671-z

Ref. 823. Sparano F, et al. (2024) JCO Oncol Pract, 20: 438. Available from: https://doi.org/10.1200/OP.23.00434

Ref. 824. Owsley KM, et al. (2025) J Cancer Surviv. Available from: https://doi.org/10.1007/s11764-025-01797-2

Ref. 825. Zhang E, et al. (2024) Blood, 144: 3650. Available from: https://doi.org/10.1182/blood-2024-200624

Ref. 826. Edward JS, et al. (2023) JCO Oncol Pract, 19: e696. Available from: https://doi.org/10.1200/OP.22.00665

Ref. 827. Domchek SM, et al. (2024) Cancer Discov, 14: 600. Available from: https://doi.org/10.1158/2159-8290.CD-24-0015

Ref. 828. Weeks LD, et al. (2023) Blood, 142: 2235. Available from: https://doi.org/10.1182/blood.2023022222

Ref. 829. Jaiswal S, et al. (2019) Science, 366. Available from: https://doi.org/10.1126/science.aan4673

Ref. 830. Kunimoto H, et al. (2017) Int J Hematol, 106: 34. Available from: https://doi.org/10.1007/s12185-017-2257-6

Ref. 831. van Zeventer IA, et al. (2023) Cancer Cell, 41: 1017. Available from: https://doi.org/10.1016/j.ccell.2023.04.006

Ref. 832. Tsai FD, et al. (2020) Blood, 136: 1615. Available from: https://doi.org/10.1182/blood.2019000990

Ref. 833. Kislikova M, et al. (2023) Life (Basel), 13. Available from: https://doi.org/10.3390/life13091801

Ref. 834. Ahmad H, et al. (2023) Annu Rev Med, 74: 249. Available from: https://doi.org/10.1146/annurev-med-042921-112347

Ref. 835. Uddin MDM, et al. (2022) Nat Commun, 13: 5350. Available from: https://doi.org/10.1038/s41467-022-33093-3

Ref. 836. Weeks LD, et al. (2023) NEJM Evid, 2. Available from: https://doi.org/10.1056/evidoa2200310

Ref. 837. Dunn WG, et al. (2024) J Clin Invest, 134. Available from: https://doi.org/10.1172/JCI180065

Ref. 838. Strati P, et al. (2015) Blood, 126: 454. Available from: https://doi.org/10.1182/blood-2015-02-585059

Ref. 839. Galigalidou C, et al. (2021) Front Oncol, 11: 769612. Available from: https://doi.org/10.3389/fonc.2021.769612

Ref. 840. Liu Y, et al. (2025) Am Soc Clin Oncol Educ Book, 45: e473650. Available from: https://doi.org/10.1200/EDBK-25-473650

Ref. 841. Serafin A, et al. (2025) Hematol Oncol, 43 Suppl 2: e70084. Available from: https://doi.org/10.1002/hon.70084

Ref. 842. Hevroni G, et al. (2024) Blood Rev, 68: 101242. Available from: https://doi.org/10.1016/j.blre.2024.101242

Ref. 843. Cordas Dos Santos DM, et al. (2024) Nat Rev Cancer, 24: 867. Available from: https://doi.org/10.1038/s41568-024-00755-x

Ref. 844. Kyle RA, et al. (2018) N Engl J Med, 378: 241. Available from: https://doi.org/10.1056/NEJMoa1709974

Ref. 845. Murray D, et al. (2019) Blood Cancer J, 9: 102. Available from: https://doi.org/10.1038/s41408-019-0263-z

Ref. 846. Mateos MV, et al. (2020) Blood Cancer J, 10: 102. Available from: https://doi.org/10.1038/s41408-020-00366-3

Ref. 847. Cowan A, et al. (2023) Lancet Haematol, 10: e203. Available from: https://doi.org/10.1016/S2352-3026(22)00386-6

Ref. 848. Alberge JB, et al. (2025) Nat Genet, 57: 1493. Available from: https://doi.org/10.1038/s41588-025-02196-0

Ref. 849. Lonial S, et al. (2020) J Clin Oncol, 38: 1126. Available from: https://doi.org/10.1200/JCO.19.01740

Ref. 850. Mateos MV, et al. (2013) N Engl J Med, 369: 438. Available from: https://doi.org/10.1056/NEJMoa1300439

Ref. 851. Landgren CO, et al. (2020) Leukemia, 34: 1840. Available from: https://doi.org/10.1038/s41375-020-0718-z

Ref. 852. Ghobrial IM, et al. (2024) Blood Cancer Discov, 5: 146. Available from: https://doi.org/10.1158/2643-3230.BCD-24-0022

Ref. 853. Wesson W, et al. (2022) Eur J Cancer, 167: 152. Available from: https://doi.org/10.1016/j.ejca.2021.12.037

Ref. 854. Pomeroy AE, et al. (2025) Blood Cancer Discov, 6: 254. Available from: https://doi.org/10.1158/2643-3230.BCD-24-0230

Ref. 855. Goldstein JS, et al. (2025) Blood Cancer Discov, 6: 153. Available from: https://doi.org/10.1158/2643-3230.BCD-25-0071

Ref. 856. National Cancer Institute. MyeloMATCH Precision Medicine Trials. Accessed: June 30, 2025. Available from: https://www.cancer.gov/types/leukemia/research/myelomatch-trials

Ref. 857. Tyner JW, et al. (2018) Nature, 562: 526. Available from: https://doi.org/10.1038/s41586-018-0623-z

Ref. 858. Hoff FW, et al. (2025) Blood Cancer J, 15: 55. Available from: https://doi.org/10.1038/s41408-025-01258-0

Ref. 859. Lang KM, et al. (2020) Trials, 21: 437. Available from: https://doi.org/10.1186/s13063-020-04384-1

Ref. 860. Giovagnoli A (2021) Int J Environ Res Public Health, 18. Available from: https://doi.org/10.3390/ijerph18020530

Ref. 861. Berry DA (2011) Nat Rev Clin Oncol, 9: 199. Available from: https://doi.org/10.1038/nrclinonc.2011.165

Ref. 862. van der Maas NG, et al. (2024) Blood Cancer J, 14: 56. Available from: https://doi.org/10.1038/s41408-024-01037-3

Ref. 863. Thall PF (2020) Contemp Clin Trials, 90: 105860. Available from: https://doi.org/10.1016/j.cct.2019.105860

Ref. 864. Bruck OE, et al. (2021) Blood Cancer Discov, 2: 238. Available from: https://doi.org/10.1158/2643-3230.BCD-20-0162

Ref. 865. Landgren O, et al. (2025) Blood Cancer Discov, 6: 13. Available from: https://doi.org/10.1158/2643-3230.BCD-24-0292

Ref. 866. Shi Q, et al. (2025) J Clin Oncol, 43: 1289. Available from: https://doi.org/10.1200/JCO-24-02020

Ref. 867. Munshi NC, et al. (2020) Blood Adv, 4: 5988. Available from: https://doi.org/10.1182/bloodadvances.2020002827

Ref. 868. Munir T, et al. (2025) N Engl J Med. Available from: https://doi.org/10.1056/NEJMoa2504341

Ref. 869. Perrot A, et al. (2025) N Engl J Med, 393: 425. Available from: https://doi.org/10.1056/NEJMoa2505133

Ref. 870. Cao C, et al. (2024) J Clin Oncol, 42: 2257. Available from: https://doi.org/10.1200/JCO.23.02536

Ref. 871. Zeng M, et al. (2025) J Transl Med, 23: 115. Available from: https://doi.org/10.1186/s12967-025-06151-9

Ref. 872. Wang Y, et al. (2025) J Transl Med, 23: 355. Available from: https://doi.org/10.1186/s12967-025-06379-5

Ref. 873. Warkentin MT, et al. (2025) Cancer Epidemiol Biomarkers Prev, 34: 174. Available from: https://doi.org/10.1158/1055-9965.EPI-24-0636

Ref. 874. American Cancer Society. Cancer Treatment and Survivorship Facts and Figures 2022-2024. Accessed: June 10, 2025. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/2022-cancer-treatment-and-survivorship-fandf-acs.pdf

Ref. 875. Bodelon C, et al. (2024) JAMA Netw Open, 7: e2433132. Available from: https://doi.org/10.1001/jamanetworkopen.2024.33132

Ref. 876. Sung H, et al. (2022) J Natl Cancer Inst, 114: 1095. Available from: https://doi.org/10.1093/jnci/djac091

Ref. 877. McNeish BL, et al. (2024) J Geriatr Oncol, 15: 101765. Available from: https://doi.org/10.1016/j.jgo.2024.101765

Ref. 878. Tao Z, et al. (2024) Cancer Lett, 611: 217433. Available from: https://doi.org/10.1016/j.canlet.2024.217433

Ref. 879. Lemanska A, et al. (2023) ESMO Open, 8: 102063. Available from: https://doi.org/10.1016/j.esmoop.2023.102063

Ref. 880. D’Souza RS, et al. (2025) Reg Anesth Pain Med. Available from: https://doi.org/10.1136/rapm-2024-106229

Ref. 881. Jordan B, et al. (2020) Ann Oncol, 31: 1306. Available from: https://doi.org/10.1016/j.annonc.2020.07.003

Ref. 882. Loprinzi CL, et al. (2020) J Clin Oncol, 38: 3325. Available from: https://doi.org/10.1200/JCO.20.01399

Ref. 883. Michel LL, et al. (2025) JAMA Oncol, 11: 408. Available from: https://doi.org/10.1001/jamaoncol.2025.0001

Ref. 884. Stone BV, et al. (2024) Eur Urol Oncol, 7: 563. Available from: https://doi.org/10.1016/j.euo.2023.11.020

Ref. 885. Setiawan T, et al. (2023) J Hematol Oncol, 16: 54. Available from: https://doi.org/10.1186/s13045-023-01454-0

Ref. 886. Groarke JD, et al. (2024) N Engl J Med, 391: 2291. Available from: https://doi.org/10.1056/NEJMoa2409515

Ref. 887. Zhu XA, et al. (2025) Science, 388: eadm8857. Available from: https://doi.org/10.1126/science.adm8857

Ref. 888. Mayo SJ, et al. (2024) JAMA Netw Open, 7: e2430833. Available from: https://doi.org/10.1001/jamanetworkopen.2024.30833

Ref. 889. Haywood D, et al. (2024) Support Care Cancer, 32: 480. Available from: https://doi.org/10.1007/s00520-024-08696-9

Ref. 890. Durbin SM, et al. (2025) JAMA Netw Open, 8: e252668. Available from: https://doi.org/10.1001/jamanetworkopen.2025.2668

Ref. 891. Johnson DB, et al. (2022) Nat Rev Clin Oncol, 19: 254. Available from: https://doi.org/10.1038/s41571-022-00600-w

Ref. 892. Ge MW, et al. (2025) Psychooncology, 34: e70077. Available from: https://doi.org/10.1002/pon.70077

Ref. 893. Wheldon CW, et al. (2025) Sci Rep, 15: 3914. Available from: https://doi.org/10.1038/s41598-025-85126-8

Ref. 894. Brick RS, et al. (2024) J Cancer Surviv. Available from: https://doi.org/10.1007/s11764-024-01573-8

Ref. 895. Hu X, et al. (2023) JAMA Netw Open, 6: e2251863. Available from: https://doi.org/10.1001/jamanetworkopen.2022.51863

Ref. 896. Liu Q, et al. (2024) Transl Psychiatry, 14: 213. Available from: https://doi.org/10.1038/s41398-024-02917-9

Ref. 897. Matsuo K, et al. (2024) JAMA Netw Open, 7: e2442964. Available from: https://doi.org/10.1001/jamanetworkopen.2024.42964

Ref. 898. Kitaw TA, et al. (2025) BMJ Glob Health, 10. Available from: https://doi.org/10.1136/bmjgh-2024-017133

Ref. 899. Jafri FI, et al. (2025) JAMA Netw Open, 8: e2455941. Available from: https://doi.org/10.1001/jamanetworkopen.2024.55941

Ref. 900. Klok JM, et al. (2024) J Cancer Surviv. Available from: https://doi.org/10.1007/s11764-024-01668-2

Ref. 901. Hussaini SMQ, et al. (2024) JCO Oncol Pract: OP2400116. Available from: https://doi.org/10.1200/OP.24.00116

Ref. 902. Dhir A, et al. (2024) JAMA Netw Open, 7: e2429286. Available from: https://doi.org/10.1001/jamanetworkopen.2024.29286

Ref. 903. Chen MH, et al. (2025) JCO Oncol Pract, 21: 78. Available from: https://doi.org/10.1200/OP.23.00833

Ref. 904. McLouth LE, et al. (2021) Cancer Epidemiol Biomarkers Prev, 30: 669. Available from: https://doi.org/10.1158/1055-9965.EPI-20-1157

Ref. 905. Raghavan D, et al. (2021) JCO Oncol Pract, 17: e1433Available from: https://ascopubs.org/doi/10.1200/OP.21.00124

Ref. 906. Knight TG, et al. (2025) J Natl Compr Canc Netw, 23: 164. Available from: https://doi.org/10.6004/jnccn.2025.7010

Ref. 907. Rotz SJ, et al. (2025) J Clin Oncol, 43: 1219. Available from: https://doi.org/10.1200/JCO-24-01519

Ref. 908. Yeh JM, et al. (2025) JAMA Oncol, 11: 535. Available from: https://doi.org/10.1001/jamaoncol.2025.0236

Ref. 909. Chow EJ, et al. (2023) J Clin Oncol, 41: 2248. Available from: https://doi.org/10.1200/JCO.22.02423

Ref. 910. Somekh MR, et al. (2024) J Natl Cancer Inst, 116: 1952. Available from: https://doi.org/10.1093/jnci/djae194

Ref. 911. Pizzo A, et al. (2024) JAMA Netw Open, 7: e2436144. Available from: https://doi.org/10.1001/jamanetworkopen.2024.36144

Ref. 912. Tan JY, et al. (2025) JAMA Netw Open, 8: e2457544. Available from: https://doi.org/10.1001/jamanetworkopen.2024.57544

Ref. 913. Perera F, et al. (2022) N Engl J Med, 386: 2303. Available from: https://doi.org/10.1056/NEJMra2117706

Ref. 914. Cheng I, et al. (2022) Environ Int, 161: 107088. Available from: https://doi.org/10.1016/j.envint.2022.107088

Ref. 915. George PE, et al. (2024) Cancer, 130: 3870. Available from: https://doi.org/10.1002/cncr.35484

Ref. 916. NCI Childhood Cancer Data Initiative. NCI NCCR*Explorer. Accessed: June 15, 2025. Available from: https://nccrexplorer.ccdi.cancer.gov/application.html

Ref. 917. Armenian SH, et al. (2024) J Clin Oncol, 42: 735. Available from: https://doi.org/10.1200/JCO.23.01751

Ref. 918. Cromie KJ, et al. (2025) Diabetes Care, 48: 519. Available from: https://doi.org/10.2337/dc24-2171

Ref. 919. Chao C, et al. (2020) Journal of Clinical Oncology, 38: 3161. Available from: https://doi.org/10.1200/Jco.20.00722

Ref. 920. van der Meer DJ, et al. (2024) Oncologist, 29: e526. Available from: https://doi.org/10.1093/oncolo/oyad307

Ref. 921. Kooijmans ECM, et al. (2025) J Clin Oncol: JCO2402534. Available from: https://doi.org/10.1200/JCO-24-02534

Ref. 922. Anderson C, et al. (2024) JNCI Cancer Spectr, 8. Available from: https://doi.org/10.1093/jncics/pkad106

Ref. 923. Murphy CC, et al. (2025) J Natl Cancer Inst, 117: 1008. Available from: https://doi.org/10.1093/jnci/djae347

Ref. 924. Su HI, et al. (2025) J Clin Oncol, 43: 1488. Available from: https://doi.org/10.1200/JCO-24-02782

Ref. 925. Alliance for Fertility Preservation. State Laws & Legislation. Accessed: June 30, 2025. Available from: https://www.allianceforfertilitypreservation.org/state-legislation/

Ref. 926. McGrady ME, et al. (2024) J Clin Oncol, 42: 707. Available from: https://doi.org/10.1200/JCO.23.01465

Ref. 927. Zhang A, et al. (2025) JAMA Netw Open, 8: e2511430. Available from: https://doi.org/10.1001/jamanetworkopen.2025.11430

Ref. 928. Parsons SK, et al. (2024) JNCI Cancer Spectr, 8. Available from: https://doi.org/10.1093/jncics/pkae071

Ref. 929. Myers SP, et al. (2024) JAMA Netw Open, 7: e2446091. Available from: https://doi.org/10.1001/jamanetworkopen.2024.46091

Ref. 930. Marchak JG, et al. (2023) J Cancer Surviv, 17: 342. Available from: https://doi.org/10.1007/s11764-023-01351-y

Ref. 931. Ehrhardt MJ, et al. (2024) J Clin Oncol, 42: 743. Available from: https://doi.org/10.1200/JCO.23.01504

Ref. 932. Salsman JM, et al. (2024) Cancer, 130: 1031. Available from: https://doi.org/10.1002/cncr.35182

Ref. 933. Bluethmann SM, et al. (2016) Cancer Epidemiol Biomarkers Prev, 25: 1029. Available from: https://doi.org/10.1158/1055-9965.EPI-16-0133

Ref. 934. Duchesneau ED, et al. (2025) JAMA Netw Open, 8: e250614. Available from: https://doi.org/10.1001/jamanetworkopen.2025.0614

Ref. 935. Rees-Punia E, et al. (2023) JAMA Oncol, 9: 79. Available from: https://doi.org/10.1001/jamaoncol.2022.5153

Ref. 936. Ye C, et al. (2024) JAMA Oncol, 10: 1554. Available from: https://doi.org/10.1001/jamaoncol.2024.4318

Ref. 937. Kleckner AS, et al. (2022) JCO Oncol Pract, 18: e9. Available from: https://doi.org/10.1200/OP.21.00196

Ref. 938. Williams GR, et al. (2018) Oncologist, 23: 433. Available from: https://doi.org/10.1634/theoncologist.2017-0404

Ref. 939. Chen W, et al. (2024) J Natl Cancer Inst, 116: 1730. Available from: https://doi.org/10.1093/jnci/djae163

Ref. 940. Hardell KNL, et al. (2024) JNCI Cancer Spectr, 8. Available from: https://doi.org/10.1093/jncics/pkae036

Ref. 941. Mohamed MR, et al. (2023) Cancer, 129: 1096. Available from: https://doi.org/10.1002/cncr.34642

Ref. 942. Oliveira RF, et al. (2024) BMC Geriatr, 24: 557. Available from: https://doi.org/10.1186/s12877-024-05135-6

Ref. 943. Bhatia R, et al. (2022) Curr Oncol Rep, 24: 1401. Available from: https://doi.org/10.1007/s11912-022-01311-2

Ref. 944. Guida JL, et al. (2019) J Natl Cancer Inst, 111: 1245. Available from: https://doi.org/10.1093/jnci/djz136

Ref. 945. Wang M, et al. (2024) J Clin Oncol, 42: 1553. Available from: https://doi.org/10.1200/JCO.23.01260

Ref. 946. Locquet M (2025) Arch Gerontol Geriatr, 134: 105858. Available from: https://doi.org/10.1016/j.archger.2025.105858

Ref. 947. Sedrak MS, et al. (2021) J Am Geriatr Soc, 69: 3077. Available from: https://doi.org/10.1111/jgs.17461

Ref. 948. Magnuson A, et al. (2024) CA Cancer J Clin, 74: 496. Available from: https://doi.org/10.3322/caac.21864

Ref. 949. Wang S, et al. (2024) Int J Mol Sci, 25. Available from: https://doi.org/10.3390/ijms25063319

Ref. 950. Birch K, et al. (2023) JCO Oncol Pract, 19: e660. Available from: https://doi.org/10.1200/OP.22.00555

Ref. 951. Zhao J, et al. (2024) J Natl Compr Canc Netw, 22: 244. Available from: https://doi.org/10.6004/jnccn.2023.7114

Ref. 952. Myers S, et al. (2025) Support Care Cancer, 33: 339. Available from: https://doi.org/10.1007/s00520-025-09393-x

Ref. 953. Pak TY (2025) Health Econ Rev, 15: 22. Available from: https://doi.org/10.1186/s13561-025-00596-w

Ref. 954. Gupta A, et al. (2024) JCO Oncol Pract, 20: 943. Available from: https://doi.org/10.1200/OP.23.00590

Ref. 955. Giles C, et al. (2019) BMJ, 366: l5120. Available from: https://doi.org/10.1136/bmj.l5120

Ref. 956. Molenaar CJL, et al. (2023) JAMA Surg, 158: 572. Available from: https://doi.org/10.1001/jamasurg.2023.0198

Ref. 957. Bai XL, et al. (2025) Br J Sports Med. Available from: https://doi.org/10.1136/bjsports-2024-109392

Ref. 958. Rees-Punia E, et al. (2025) J Natl Cancer Inst. Available from: https://doi.org/10.1093/jnci/djaf112

Ref. 959. Wilson OW, et al. (2025) Cancer Epidemiol Biomarkers Prev. Available from: https://doi.org/10.1158/1055-9965.EPI-24-1798

Ref. 960. Rayner CJ, et al. (2025) J Sport Health Sci: 101063. Available from: https://doi.org/10.1016/j.jshs.2025.101063

Ref. 961. Courneya KS, et al. (2025) N Engl J Med. Available from: https://doi.org/10.1056/NEJMoa2502760

Ref. 962. Streckmann F, et al. (2024) JAMA Intern Med, 184: 1046. Available from: https://doi.org/10.1001/jamainternmed.2024.2354

Ref. 963. Engh A, et al. (2025) Gynecol Oncol, 195: 82. Available from: https://doi.org/10.1016/j.ygyno.2025.03.009

Ref. 964. Ulrich CM, et al. (2025) JAMA Surg, 160: 495. Available from: https://doi.org/10.1001/jamasurg.2025.0130

Ref. 965. Galvao DA, et al. (2025) JAMA Netw Open, 8: e250413. Available from: https://doi.org/10.1001/jamanetworkopen.2025.0413

Ref. 966. Soong RY, et al. (2025) JAMA Netw Open, 8: e2457859. Available from: https://doi.org/10.1001/jamanetworkopen.2024.57859

Ref. 967. Wang A, et al. (2025) JAMA Netw Open, 8: e2460785. Available from: https://doi.org/10.1001/jamanetworkopen.2024.60785

Ref. 968. Hang D, et al. (2024) EClinicalMedicine, 71: 102572. Available from: https://doi.org/10.1016/j.eclinm.2024.102572

Ref. 969. Lan T, et al. (2024) Br J Cancer, 131: 1169. Available from: https://doi.org/10.1038/s41416-024-02815-3

Ref. 970. Lin JC, et al. (2025) JAMA Health Forum, 6: e251381. Available from: https://doi.org/10.1001/jamahealthforum.2025.1381

Ref. 971. Patel KB, et al. (2024) Gynecol Oncol, 188: 8. Available from: https://doi.org/10.1016/j.ygyno.2024.05.029

Ref. 972. Demark-Wahnefried W, et al. (2024) JAMA Netw Open, 7: e2417122. Available from: https://doi.org/10.1001/jamanetworkopen.2024.17122

Ref. 973. Nolazco JI, et al. (2023) Front Oncol, 13: 1261041. Available from: https://doi.org/10.3389/fonc.2023.1261041

Ref. 974. US Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress A Report of the Surgeon General. Accessed: March 17, 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK179276/

Ref. 975. Sanford NN, et al. (2019) JAMA Oncol, 5: 426. Available from: https://doi.org/10.1001/jamaoncol.2018.6858

Ref. 976. Lopez-Olivo MA, et al. (2024) J Cancer Surviv, 18: 1059. Available from: https://doi.org/10.1007/s11764-023-01357-6

Ref. 977. Powers JM, et al. (2025) Cancer, 131: e35701. Available from: https://doi.org/10.1002/cncr.35701

Ref. 978. Avancena ALV, et al. (2025) J Natl Compr Canc Netw, 23: 156. Available from: https://doi.org/10.6004/jnccn.2025.7007

Ref. 979. Heffner JL, et al. (2024) Cancer Epidemiol Biomarkers Prev, 33: 600. Available from: https://doi.org/10.1158/1055-9965.EPI-23-1155

Ref. 980. Avancena ALV, et al. (2025) Ann Intern Med. Available from: https://doi.org/10.7326/ANNALS-24-02679

Ref. 981. Kang E, et al. (2024) JAMA Netw Open, 7: e2426304. Available from: https://doi.org/10.1001/jamanetworkopen.2024.26304

Ref. 982. Mah SJ, et al. (2024) JAMA Netw Open, 7: e2440977. Available from: https://doi.org/10.1001/jamanetworkopen.2024.40977

Ref. 983. Petrillo LA, et al. (2024) Am Soc Clin Oncol Educ Book, 44: e100038. Available from: https://doi.org/10.1200/EDBK_100038

Ref. 984. Hart NH, et al. (2024) Support Care Cancer, 32: 313. Available from: https://doi.org/10.1007/s00520-024-08465-8

Ref. 985. Jefford M, et al. (2025) Am Soc Clin Oncol Educ Book, 45: e471752. Available from: https://doi.org/10.1200/EDBK-25-471752

Ref. 986. Sanders JJ, et al. (2024) J Clin Oncol: JCO2400542. Available from: https://doi.org/10.1200/JCO.24.00542

Ref. 987. Kwon Y, et al. (2025) JAMA Health Forum, 6: e245436. Available from: https://doi.org/10.1001/jamahealthforum.2024.5436

Ref. 988. Temel JS, et al. (2024) JAMA, 332: 471. Available from: https://doi.org/10.1001/jama.2024.10398

Ref. 989. Stal J, et al. (2024) JAMA Netw Open, 7: e2418736. Available from: https://doi.org/10.1001/jamanetworkopen.2024.18736

Ref. 990. Nekhlyudov L, et al. (2024) JAMA Netw Open, 7: e2418686. Available from: https://doi.org/10.1001/jamanetworkopen.2024.18686

Ref. 991. Bergerot CD, et al. (2025) JCO Glob Oncol, 11: e2400625. Available from: https://doi.org/10.1200/GO-24-00625

Ref. 992. Hahn EE, et al. (2022) JAMA, 327: 41. Available from: https://doi.org/10.1001/jama.2021.22596

Ref. 993. Kulchycki M, et al. (2024) JAMA Netw Open, 7: e2437964. Available from: https://doi.org/10.1001/jamanetworkopen.2024.37964

Ref. 994. Smith A, et al. (2024) J Cancer Surviv. Available from: https://doi.org/10.1007/s11764-024-01685-1

Ref. 995. Caldiroli CL, et al. (2025) Sci Rep, 15: 8599. Available from: https://doi.org/10.1038/s41598-025-93008-2

Ref. 996. Rosenberg AR, et al. (2025) JCO Oncol Pract: OP2500161. Available from: https://doi.org/10.1200/OP-25-00161

Ref. 997. Rosenberg AR, et al. (2021) JAMA Netw Open, 4: e2136039. Available from: https://doi.org/10.1001/jamanetworkopen.2021.36039

Ref. 998. Salsman JM, et al. (2023) Int J Behav Med, 30: 639. Available from: https://doi.org/10.1007/s12529-023-10162-5

Ref. 999. Ver Hoeve ES, et al. (2024) BMC Health Serv Res, 24: 550. Available from: https://doi.org/10.1186/s12913-024-10919-y

Ref. 1000. Gany F, et al. (2025) J Natl Compr Canc Netw: 1. Available from: https://doi.org/10.6004/jnccn.2025.7017

Ref. 1001. Santos-Teles M, et al. (2024) Support Care Cancer, 32: 798. Available from: https://doi.org/10.1007/s00520-024-08986-2

Ref. 1002. Tsai MH, et al. (2024) J Cancer Surviv, 18: 781. Available from: https://doi.org/10.1007/s11764-022-01309-6

Ref. 1003. Atlas SJ, et al. (2025) JCO Oncol Pract, 21: 123. Available from: https://doi.org/10.1200/OP.23.00818

Ref. 1004. Singh AP, et al. (2025) JCO Oncol Pract, 21: 128. Available from: https://doi.org/10.1200/OP.24.00260

Ref. 1005. Birken SA, et al. (2025) JCO Oncol Pract, 21: 766. Available from: https://doi.org/10.1200/OP.23.00699

Ref. 1006. Mollica MA, et al. (2024) J Cancer Surviv, 18: 1190. Available from: https://doi.org/10.1007/s11764-024-01602-6

Ref. 1007. Manne S, et al. (2024) J Cancer Surviv, 18: 1. Available from: https://doi.org/10.1007/s11764-023-01528-5

Ref. 1008. Oluwole SF, et al. (2003) J Am Coll Surg, 196: 180. Available from: https://doi.org/10.1016/s1072-7515(02)01765-9

Ref. 1009. Causey L, et al. (2025) Clin J Oncol Nurs, 29: E60. Available from: https://doi.org/10.1188/25.CJON.E60-E69

Ref. 1010. Edward J, et al. (2024) JNCI Cancer Spectr, 8. Available from: https://doi.org/10.1093/jncics/pkae025

Ref. 1011. Hong M, et al. (2024) Neurooncol Pract, 11: 575. Available from: https://doi.org/10.1093/nop/npae030

Ref. 1012. Wheeler SB, et al. (2024) J Natl Compr Canc Netw, 22: 557. Available from: https://doi.org/10.6004/jnccn.2024.7030

Ref. 1013. Basch E, et al. (2024) JAMA, 332: 1979. Available from: https://doi.org/10.1001/jama.2024.17371

Ref. 1014. Colbert JA, et al. (2025) JAMA Oncol, 11: 233. Available from: https://doi.org/10.1001/jamaoncol.2024.6157

Ref. 1015. Rocque GB, et al. (2025) JAMA Netw Open, 8: e259852. Available from: https://doi.org/10.1001/jamanetworkopen.2025.9852

Ref. 1016. Basch E, et al. (2025) Nat Med, 31: 1225. Available from: https://doi.org/10.1038/s41591-025-03507-y

Ref. 1017. Dupuis LL, et al. (2025) JAMA Pediatr, 179: 11. Available from: https://doi.org/10.1001/jamapediatrics.2024.4727

Ref. 1018. National Partnership for Women and Families. Paid Leave Could Keep More Than 6 Million Caregivers Connected to the Labor Force by 2030. Accessed: March 26, 2025. Available from: https://nationalpartnership.org/wp-content/uploads/2023/02/paid-leave-caregivers-connected-2030.pdf

Ref. 1019. Choudry MM, et al. (2024) Cancer, 130: 4061. Available from: https://doi.org/10.1002/cncr.35486

Ref. 1020. Klekovkina E, et al. (2025) Archives of Gerontology and Geriatrics Plus, 2: 100141

Ref. 1021. Liu Q, et al. (2024) JAMA Oncol, 10: 1323. Available from: https://doi.org/10.1001/jamaoncol.2024.3036

Ref. 1022. Mahmood A, et al. (2025) Support Care Cancer, 33: 75. Available from: https://doi.org/10.1007/s00520-024-09133-7

Ref. 1023. Yang T, et al. (2025) BMC Psychiatry, 25: 97. Available from: https://doi.org/10.1186/s12888-025-06546-4

Ref. 1024. Anant S, et al. (2025) JCO Oncol Pract, 21: 41. Available from: https://doi.org/10.1200/OP.24.00305

Ref. 1025. Administration for Community Living. 2022 National Strategy to Support Family Caregivers. Accessed: June 21, 2025. Available from: https://acl.gov/sites/default/files/RAISE_SGRG/NatlStrategyToSupportFamilyCaregivers-2.pdf

Ref. 1026. Odom JN, et al. (2023) JAMA Netw Open, 6: e2337250. Available from: https://doi.org/10.1001/jamanetworkopen.2023.37250

Ref. 1027. Gong D, et al. (2024) Cancer Cell, 42: 1653. Available from: https://doi.org/10.1016/j.ccell.2024.09.001

Ref. 1028. Verstegen MMA, et al. (2025) Nat Med, 31: 409. Available from: https://doi.org/10.1038/s41591-024-03489-3

Ref. 1029. Peng Z, et al. (2025) Mol Cancer, 24: 93. Available from: https://doi.org/10.1186/s12943-025-02281-2

Ref. 1030. Chang TG, et al. (2025) Nat Cancer, 6: 417. Available from: https://doi.org/10.1038/s43018-025-00917-2

Ref. 1031. Loaiza-Bonilla A, et al. (2025) Am Soc Clin Oncol Educ Book, 45: e100048. Available from: https://doi.org/10.1200/EDBK-25-100048

Ref. 1032. Dimitrieva S, et al. (2025) Sci Adv, 11: eadn5596. Available from: https://doi.org/10.1126/sciadv.adn5596

Ref. 1033. Barbadilla-Martinez L, et al. (2025) Nat Rev Genet. Available from: https://doi.org/10.1038/s41576-025-00841-2

Ref. 1034. Qiu W, et al. (2025) Nat Biomed Eng, 9: 333. Available from: https://doi.org/10.1038/s41551-024-01290-8

Ref. 1035. Niu C, et al. (2025) Nat Commun, 16: 1523. Available from: https://doi.org/10.1038/s41467-025-56822-w

Ref. 1036. Mekala S, et al. (2025) Sci Rep, 15: 19787. Available from: https://doi.org/10.1038/s41598-025-00512-6

Ref. 1037. Sheakh MA, et al. (2025) Computer Methods and Programs in Biomedicine Update, 7: 100181. Available from: https://doi.org/10.1016/j.cmpbup.2025.100181

Ref. 1038. Lee D, et al. (2025) Sci Rep, 15: 10995. Available from: https://doi.org/10.1038/s41598-025-94183-y

Ref. 1039. Mathios D, et al. (2025) Cancer Discov. Available from: https://doi.org/10.1158/2159-8290.CD-25-0074

Ref. 1040. Zhao Y, et al. (2025) Lancet Oncol, 26: 136. Available from: https://doi.org/10.1016/S1470-2045(24)00599-0

Ref. 1041. Hourfar H, et al. (2025) Clin Oncol (R Coll Radiol), 40: 103789. Available from: https://doi.org/10.1016/j.clon.2025.103789

Ref. 1042. Ritter M, et al. (2025) Nat Cancer, 6: 292. Available from: https://doi.org/10.1038/s43018-024-00904-z

Ref. 1043. Yuan D, et al. (2025) Nat Cancer. Available from: https://doi.org/10.1038/s43018-025-00976-5

Ref. 1044. Najafian K, et al. (2024) Neurooncol Adv, 6: vdae200. Available from: https://doi.org/10.1093/noajnl/vdae200

Ref. 1045. Zhang Y, et al. (2025) Nat Commun, 16: 4444. Available from: https://doi.org/10.1038/s41467-025-59433-7

Ref. 1046. Kovacs KA, et al. (2025) Sci Rep, 15: 4868. Available from: https://doi.org/10.1038/s41598-025-89339-9

Ref. 1047. Callaway E (2024) Nature, 634: 525. Available from: https://doi.org/10.1038/d41586-024-03214-7

Ref. 1048. Mao Y, et al. (2025) Mol Cancer, 24: 123. Available from: https://doi.org/10.1186/s12943-025-02321-x

Ref. 1049. Mishra V, et al. (2025) J Exp Clin Cancer Res, 44: 11. Available from: https://doi.org/10.1186/s13046-024-03270-x

Ref. 1050. Su X, et al. (2025) Nat Biomed Eng, 9: 371. Available from: https://doi.org/10.1038/s41551-024-01312-5

Ref. 1051. Tosh C, et al. (2025) Nat Commun, 16: 156. Available from: https://doi.org/10.1038/s41467-024-55287-7

Ref. 1052. Pourmousa M, et al. (2025) Nat Commun, 16: 4020. Available from: https://doi.org/10.1038/s41467-025-56818-6

Ref. 1053. Dong X, et al. (2025) NPJ Precis Oncol, 9: 36. Available from: https://doi.org/10.1038/s41698-025-00813-z

Ref. 1054. Mollica L, et al. (2024) ESMO Real World Data and Digital Oncology, 5: 100056. Available from: https://doi.org/10.1016/j.esmorw.2024.100056

Ref. 1055. Chen X, et al. (2025) Nat Commun, 16: 4086. Available from: https://doi.org/10.1038/s41467-025-59200-8

Ref. 1056. Goh E, et al. (2025) Nat Med, 31: 1233. Available from: https://doi.org/10.1038/s41591-024-03456-y

Ref. 1057. Ferber D, et al. (2025) Nat Cancer. Available from: https://doi.org/10.1038/s43018-025-00991-6

Ref. 1058. Bai Z, et al. (2025) NPJ Digit Med, 8: 174. Available from: https://doi.org/10.1038/s41746-025-01560-y

Ref. 1059. Jee J, et al. (2024) Nature, 636: 728. Available from: https://doi.org/10.1038/s41586-024-08167-5

Ref. 1060. Keyl J, et al. (2025) Nat Cancer, 6: 307. Available from: https://doi.org/10.1038/s43018-024-00891-1

Ref. 1061. Chia S, et al. (2025) Cell Rep Med, 6: 102053. Available from: https://doi.org/10.1016/j.xcrm.2025.102053

Ref. 1062. Butt RN, et al. (2025) Sci Rep, 15: 15080. Available from: https://doi.org/10.1038/s41598-025-99219-x

Ref. 1063. Blasiak A, et al. (2025) NPJ Precis Oncol, 9: 49. Available from: https://doi.org/10.1038/s41698-025-00835-7

Ref. 1064. Mahmood F (2025) Nat Med, 31: 1060. Available from: https://doi.org/10.1038/s41591-025-03637-3

Ref. 1065. Ratwani RM, et al. (2024) JAMA, 332: 1051. Available from: https://doi.org/10.1001/jama.2024.13486

Ref. 1066. Dankwa-Mullan I, et al. (2025) Curr Oncol Rep, 27: 95. Available from: https://doi.org/10.1007/s11912-024-01627-1

Ref. 1067. Belli O, et al. (2024) Nat Biotechnol. Available from: https://doi.org/10.1038/s41587-024-02439-1

Ref. 1068. Pagliaro A, et al. (2025) Nat Protoc. Available from: https://doi.org/10.1038/s41596-024-01107-7

Ref. 1069. Du Y, et al. (2025) Oncogene, 44: 409. Available from: https://doi.org/10.1038/s41388-025-03273-8

Ref. 1070. Fong SH, et al. (2025) Nat Genet, 57: 154. Available from: https://doi.org/10.1038/s41588-024-01971-9

Ref. 1071. Patel RP, et al. (2024) Sci Immunol, 9: eadn6509. Available from: https://doi.org/10.1126/sciimmunol.adn6509

Ref. 1072. Rea A, et al. (2025) Nat Immunol, 26: 582. Available from: https://doi.org/10.1038/s41590-025-02103-z

Ref. 1073. Lou E, et al. (2025) Lancet Oncol, 26: 559. Available from: https://doi.org/10.1016/S1470-2045(25)00083-X

Ref. 1074. Feng X, et al. (2024) Exp Hematol Oncol, 13: 102. Available from: https://doi.org/10.1186/s40164-024-00570-y

Ref. 1075. Tarannum M, et al. (2025) Nat Biotechnol, 43: 516. Available from: https://doi.org/10.1038/s41587-025-02629-5

Ref. 1076. Khoshandam M, et al. (2024) Genes Dis, 11: 101121. Available from: https://doi.org/10.1016/j.gendis.2023.101121

Ref. 1077. Xu W, et al. (2024) J Transl Med, 22: 1133. Available from: https://doi.org/10.1186/s12967-024-05957-3

Ref. 1078. Li Q, et al. (2025) ACS Appl Mater Interfaces, 17: 4480. Available from: https://doi.org/10.1021/acsami.4c15671

Ref. 1079. Masarwy R, et al. (2025) Adv Sci (Weinh), 12: e2411032. Available from: https://doi.org/10.1002/advs.202411032

Ref. 1080. Lei S, et al. (2025) Leukemia, 39: 420. Available from: https://doi.org/10.1038/s41375-024-02461-x

Ref. 1081. Leiting JL, et al. (2025) Ann Surg Oncol, 32: 4453. Available from: https://doi.org/10.1245/s10434-025-17036-y

Ref. 1082. Jazieh K, et al. (2025) Clin Cancer Res, 31: 899. Available from: https://doi.org/10.1158/1078-0432.CCR-24-2948

Ref. 1083. Murciano-Goroff YR, et al. (2024) JCO Precis Oncol, 8: e2400216. Available from: https://doi.org/10.1200/PO.24.00216

Ref. 1084. Stutheit-Zhao EY, et al. (2024) Cancer Discov, 14: 1048. Available from: https://doi.org/10.1158/2159-8290.CD-23-1060

Ref. 1085. Janssen FW, et al. (2024) NPJ Precis Oncol, 8: 172. Available from: https://doi.org/10.1038/s41698-024-00657-z

Ref. 1086. Nakamura Y, et al. (2024) Nat Med, 30: 3272. Available from: https://doi.org/10.1038/s41591-024-03254-6

Ref. 1087. Tie J, et al. (2025) Nat Med, 31: 1509. Available from: https://doi.org/10.1038/s41591-025-03579-w

Ref. 1088. Basu A, et al. (2024) JCO Precis Oncol, 8: e2400667. Available from: https://doi.org/10.1200/PO-24-00667

Ref. 1089. Syeda MM, et al. (2025) Lancet Oncol, 26: 641. Available from: https://doi.org/10.1016/S1470-2045(25)00139-1

Ref. 1090. Mayadev J, et al. (2025) Ann Oncol. Available from: https://doi.org/10.1016/j.annonc.2025.05.533

Ref. 1091. Bartolomucci A, et al. (2025) NPJ Precis Oncol, 9: 84. Available from: https://doi.org/10.1038/s41698-025-00876-y

Ref. 1092. Perica K, et al. (2025) Nature, 640: 793. Available from: https://doi.org/10.1038/s41586-025-08657-0

Ref. 1093. Park S, et al. (2024) NPJ Precis Oncol, 8: 279. Available from: https://doi.org/10.1038/s41698-024-00753-0

Ref. 1094. Haldar SD, et al. (2024) Cancer Research, 84: CT022. Available from: https://doi.org/10.1158/1538-7445.Am2024-ct022

Ref. 1095. Graciotti M, et al. (2025) Nat Rev Drug Discov, 24: 134. Available from: https://doi.org/10.1038/s41573-024-01081-5

Ref. 1096. Zaidi N, et al. (2025) Nat Rev Cancer. Available from: https://doi.org/10.1038/s41568-025-00820-z

Ref. 1097. Martini DJ, et al. (2025) Cancer Discov. Available from: https://doi.org/10.1158/2159-8290.CD-25-0300

Ref. 1098. Sethna Z, et al. (2025) Nature, 639: 1042. Available from: https://doi.org/10.1038/s41586-024-08508-4

Ref. 1099. Soliman H, et al. (2025) NPJ Breast Cancer, 11: 29. Available from: https://doi.org/10.1038/s41523-025-00742-x

Ref. 1100. Bear AS, et al. (2024) J Clin Invest, 134. Available from: https://doi.org/10.1172/JCI175790

Ref. 1101. Braun DA, et al. (2025) Nature, 639: 474. Available from: https://doi.org/10.1038/s41586-024-08507-5

Ref. 1102. Liang KL, et al. (2025) Cancers (Basel), 17. Available from: https://doi.org/10.3390/cancers17071246

Ref. 1103. Saxena M, et al. (2025) Cancer Discov, 15: 930. Available from: https://doi.org/10.1158/2159-8290.CD-24-0934

Ref. 1104. Brenner AJ, et al. (2025) Nat Commun, 16: 2079. Available from: https://doi.org/10.1038/s41467-025-57263-1

Ref. 1105. National Institutes of Health. Grants & Funding. Accessed: June 12, 2025. Available from: https://www.nih.gov/grants-funding

Ref. 1106. National Institutes of Health. National Cancer Institute. Accessed: June 12, 2025. Available from: https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-cancer-institute-nci

Ref. 1107. National Institutes of Health. Advanced Research Projects Agency for Health (ARPA-H). Accessed: June 12, 2025. Available from: https://www.nih.gov/arpa-h

Ref. 1108. ARPAH Programs. Accessed: June 1, 2025. Available from: https://arpa-h.gov/explore-funding/programs

Ref. 1109. US Food & Drug Administration. OCE Programs and Projects Overview. Accessed: June 12, 2025. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/oce-programs-and-projects-overview

Ref. 1110. US Food & Drug Administration. Center for Tobacco Products. Accessed: June 12, 2025. Available from: https://www.fda.gov/about-fda/fda-organization/center-tobacco-products

Ref. 1111. Centers for Disease Control and Prevention. Colorectal Cancer Control Program. Award Recipient Highlights. Accessed: March 17, 2025. Available from: https://www.cdc.gov/cancer/crccp/success/

Ref. 1112. Agency for Healthcare Research and Quality. Research Training and Education. Accessed: June 2, 2025. Available from: https://www.ahrq.gov/funding/training-grants/index.html

Ref. 1113. Vyas JM, et al. (2024) JAMA Netw Open, 7: e2433123. Available from: https://doi.org/10.1001/jamanetworkopen.2024.33123

Ref. 1114. Schmidt M, et al. (2024) J Cancer Educ, 39: 490. Available from: https://doi.org/10.1007/s13187-024-02420-1

Ref. 1115. Ferguson MA, et al. (2025) J Cancer Educ, 40: 359. Available from: https://doi.org/10.1007/s13187-024-02514-w

Ref. 1116. Garisto D (2025) Nature. Available from: https://doi.org/10.1038/d41586-025-00608-z

Ref. 1117. The Transmitter. Exclusive: NIH nixes funds for pre-and postdoctoral training programs. Accessed: June 30, 2025. Available from: https://www.thetransmitter.org/funding/exclusive-nih-nixes-funds-for-several-pre-and-postdoctoral-training-programs/

Ref. 1118. CalMatters. Another casualty of Trump cuts? California students pursuing science research careers. Accessed: June 30, 2025. Available from: https://calmatters.org/education/higher-education/2025/05/nih-science-research-california/

Ref. 1119. Congress.gov. H.R.3746 – 118th Congress (2023-2024): Fiscal Responsibility Act of 2023. Accessed: June 12, 2028. Available from: https://www.congress.gov/bill/118th-congress/house-bill/3746/summary/00

Ref. 1120. Woolston C (2023) Nature, 613: 601. Available from: https://doi.org/10.1038/d41586-023-00088-z

Ref. 1121. Harvard Gazette. How progress happens. Accessed: June 30, 2025. Available from: https://news.harvard.edu/gazette/story/2025/02/how-progress-happens/

Ref. 1122. The State of the US Biomedical and Health Research Enterprise: Strategies for Achieving a Healthier America. Accessed: July 1, 2025. Available from: https://nap.nationalacademies.org/catalog/27588/the-state-of-the-us-biomedical-and-health-research-enterprise

Ref. 1123. National Institutes of Health. NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates. Accessed: June 30, 2025. Available from: https://www.ncbi.nlm.nih.gov/pubmed/

Ref. 1124. STAT News. Trump administration orders NIH to eliminate $2.6 billion in federal contracts. Accessed: June 30, 2025. Available from: https://www.statnews.com/2025/04/03/nih-35-percent-cut-contracts-trump-administration/

Ref. 1125. Gomez LE, et al. (2019) J Natl Med Assoc, 111: 383. Available from: https://doi.org/10.1016/j.jnma.2019.01.006

Ref. 1126. Zhou J, et al. (2019) J Natl Cancer Inst, 111: 449. Available from: https://doi.org/10.1093/jnci/djy130

Ref. 1127. US Food and Drug Administration. Project Optimus. Accessed: June 30, 2025. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus

Ref. 1128. US Food & Drug Administration. Oncology Center of Excellence. Accessed: June 12, 2025. Available from: https://www.fda.gov/about-fda/fda-organization/oncology-center-excellence

Ref. 1129. US Food and Drug Administration. Project Pragmatica. Accessed: June 30, 2025. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/project-pragmatica

Ref. 1130. Suehnholz SP, et al. (2024) Journal of Clinical Oncology, 42: e13507. Available from: https://doi.org/10.1200/JCO.2024.42.16_suppl.e13507

Ref. 1131. US Food and Drug Administration. September 26, 2024: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement – 09/26/2024. Accessed: June 30, 2025. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024

Ref. 1132. US Food and Drug Administration. May 20-21, 2025: Meeting of the Oncologic Drugs Advisory Committee – 05/20/2025. Accessed: June 30, 2025. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025

Ref. 1133. US Food and Drug Administration. FDA approves updated drug labeling including new indications and dosing regimens for capecitabine tablets under Project Renewal. Accessed: June 30, 2025. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-updated-drug-labeling-including-new-indications-and-dosing-regimens-capecitabine

Ref. 1134. US Food and Drug Administration. FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products. Accessed: June 30, 2025. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-safety-labeling-changes-regarding-dpd-deficiency-fluorouracil-injection-products

Ref. 1135. American Association for Cancer Research. 2025 FDA-AACR Workshop: DPD Deficiency and Weighing Potential Harms. Accessed: June 30, 2025. Available from: https://www.aacr.org/professionals/policy-and-advocacy/regulatory-science-and-policy/events/2025-fda-aacr-workshop-dpd-deficiency-and-weighing-potential-harms/

Ref. 1136. Federal Registrar. Dihydropyrimidine Dehydrogenase Deficiency and the Use of Fluoropyrimidine Chemotherapy Drugs; Establishment of a Public Docket; Request for Comments. Accessed: June 30, 2025. Available from: https://www.federalregister.gov/documents/2025/05/20/2025-08960/dihydropyrimidine-dehydrogenase-deficiency-and-the-use-of-fluoropyrimidine-chemotherapy-drugs

Ref. 1137. Friends of Cancer Research. 20 Years of FDA Leadership in Novel Cancer Drug Approvals. Accessed: June 30, 2025. Available from: https://friendsofcancerresearch.org/blog/20-years-of-fda-leadership-in-novel-cancer-drug-approvals/

Ref. 1138. US Food and Drug Administration. Accelerated Approval Program. Accessed: June 30, 2025. Available from: https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program

Ref. 1139. Mehta GU, et al. (2024) J Clin Oncol, 42: 3778. Available from: https://doi.org/10.1200/JCO-24-01654

Ref. 1140. US Food and Drug Administration. Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway. Accessed: June 30, 2025. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/accelerated-approval-and-considerations-determining-whether-confirmatory-trial-underway

Ref. 1141. US Food and Drug Administration. Accelerated Approval – Expedited Program for Serious Conditions. Accessed: June 30, 2025. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/accelerated-approval-expedited-program-serious-conditions

Ref. 1142. US Food and Drug Administration. FDA to Issue New Commissioner’s National Priority Vouchers to Companies Supporting US National Interests. Accessed: June 30, 2025. Available from: https://www.fda.gov/news-events/press-announcements/fda-issue-new-commissioners-national-priority-vouchers-companies-supporting-us-national-interests

Ref. 1143. US Food and Drug Administration. International Regulatory Harmonization. Accessed: June 30, 2025. Available from: https://www.fda.gov/drugs/cder-international-program/international-regulatory-harmonization

Ref. 1144. Arora S, et al. (2020) Clin Cancer Res, 26: 5062. Available from: https://doi.org/10.1158/1078-0432.CCR-19-3979

Ref. 1145. US Food and Drug Administration. Project Orbis. Accessed: June 30, 2025. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis

Ref. 1146. Maita KC, et al. (2024) Perm J, 28: 130. Available from: https://doi.org/10.7812/TPP/23.134

Ref. 1147. Coronado GD, et al. (2025) JAMA Netw Open, 8: e250928. Available from: https://doi.org/10.1001/jamanetworkopen.2025.0928

Ref. 1148. Amboree TL, et al. (2024) JAMA Intern Med, 184: 671. Available from: https://doi.org/10.1001/jamainternmed.2024.0693

Ref. 1149. Congress.gov. H.R.842 – 119th Congress (2025-2026): Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act. Accessed: June 30, 2025. Available from: https://www.congress.gov/bill/119th-congress/house-bill/842/text

Ref. 1150. Star J, et al. (2025) JAMA, 333: 1543. Available from: https://doi.org/10.1001/jama.2025.0902

Ref. 1151. Healthy People 2030. Increase the proportion of adolescents who get recommended doses of the HPV vaccine — IID-08. Accessed: June 30, 2025. Available from: https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination/increase-proportion-adolescents-who-get-recommended-doses-hpv-vaccine-iid-08

Ref. 1152. Alarid-Escudero F, et al. (2025) J Natl Cancer Inst, 117: 737. Available from: https://doi.org/10.1093/jnci/djae298

Ref. 1153. United States Preventive Services Taskforce. Draft Recommendation: Cervical Cancer: Screening. Accessed: June 30, 2025. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/cervical-cancer-screening-adults-adolescents

Ref. 1154. Dunlop KLA, et al. (2024) Prev Med, 181: 107897. Available from: https://doi.org/10.1016/j.ypmed.2024.107897

Ref. 1155. Tan NQP, et al. (2025) Lancet Public Health, 10: e85. Available from: https://doi.org/10.1016/S2468-2667(24)00278-0

Ref. 1156. Gentile F, et al. (2024) ESMO Real World Data and Digital Oncology, 5: 100046. Available from: https://doi.org/10.1016/j.esmorw.2024.100046

Ref. 1157. Lee KH, et al. (2025) Qual Manag Health Care, 34: 186. Available from: https://doi.org/10.1097/QMH.0000000000000526

Ref. 1158. Centers for Disease Control and Prevention. Breast Cancer Screening Change Package. Accessed: June 30, 2025. Available from: https://aliadoshealth.org/wp-content/uploads/2024/10/CDC-Breast-Cancer-Screening-Change-Package-2024.pdf

Ref. 1159. Centers for Disease Control and Prevention. NIOSH List of Hazardous Drugs in Healthcare Settings, 2024. Accessed: June 30, 2025. Available from: https://www.cdc.gov/niosh/docs/2025-103/pdfs/2025-103.pdf?id=10.26616/NIOSHPUB2025103

Ref. 1160. Congress.gov. H.R.2381 – 119th Congress (2025-2026): SCREENS for Cancer Act of 2025. Accessed: June 30, 2025. Available from: https://www.congress.gov/bill/119th-congress/house-bill/2381/text

Ref. 1161. Centers for Disease Control and Prevention. What CDC Is Doing to Achieve Equity in Cancer Control. Accessed: June 30, 2025. Available from: https://www.cdc.gov/cancer/health-equity/what-cdc-is-doing.html

Ref. 1162. Centers for Disease Control and Prevention. About the Division of Cancer Prevention and Control | National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). Accessed: June 12, 2025. Available from: https://www.cdc.gov/nccdphp/divisions-offices/about-the-division-of-cancer-prevention-and-control.html

Ref. 1163. Centers for Disease Control and Prevention. The Health Consequences of Smoking – 50 Years of Progress: A Report of the Surgeon General. Accessed: June 6, 2025. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24455788

Ref. 1164. Centers for Disease Control and Prevention. Tobacco-Related Mortality. Accessed: June 30, 2025. Available from: https://archive.cdc.gov/www_cdc_gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_related_mortality/index.htm

Ref. 1165. American Lung Association. Tobacco Trends Brief: Overall Tobacco Trends Brief. Accessed: June 30, 2025. Available from: https://www.lung.org/research/trends-in-lung-disease/tobacco-trends-brief/overall-smoking-trends

Ref. 1166. Truth Initiative. Tracing the racist tactics of the tobacco industry. Accessed: June 30, 2025. Available from: https://truthinitiative.org/research-resources/targeted-communities/tracing-racist-tactics-tobacco-industry

Ref. 1167. Centers for Disease Control and Prevention. LGBTQ+ People | For Specific Groups | Tips From Former Smokers. Accessed: June 30, 2025. Available from: https://www.cdc.gov/tobacco/campaign/tips/groups/lgbt.html

Ref. 1168. Truth Initiative. Outsmart Nicotine. Accessed: June 30, 2025. Available from: https://truthinitiative.org/outsmart-nicotine

Ref. 1169. Centers for Disease Control and Prevention. Five Reasons Why Calling a Quitline Can Be Key to Your Success | Quit Smoking | Tips From Former Smokers. Accessed: June 30, 2025. Available from: https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/quitline/index.html

Ref. 1170. Wang TW, et al. (2019) MMWR Surveill Summ, 68: 1. Available from: https://doi.org/10.15585/mmwr.ss6812a1

Ref. 1171. US Food and Drug Administration. Results from the Annual National Youth Tobacco Survey (NYTS). Accessed: June 30, 2025. Available from: https://www.fda.gov/tobacco-products/youth-and-tobacco/results-annual-national-youth-tobacco-survey-nyts

Ref. 1172. Centers for Disease Control and Prevention. Current Cigarette Smoking Among Adults in the United States | Smoking and Tobacco Use. Accessed: June 30, 2025. Available from: https://www.cdc.gov/tobacco/php/data-statistics/adult-data-cigarettes/index.html

Ref. 1173. American Lung Association. Lifesaving Programs to Prevent and Reduce Tobacco Use Go Up in Smoke. Accessed: June 30, 2025. Available from: https://www.lung.org/getmedia/e27f89e0-a769-4ed9-b70e-6ecfa893b390/up-in-smoke-report.pdf

Ref. 1174. Bold KW, et al. (2024) Annu Rev Clin Psychol, 20: 381. Available from: https://doi.org/10.1146/annurev-clinpsy-080921-075624

Ref. 1175. Reuters. Trump administration withdraws FDA plan to ban menthol cigarettes. Accessed: June 30, 2025. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/trump-administration-withdraws-fda-plan-ban-menthol-cigarettes-2025-01-24/

Ref. 1176. Campaign for Tobacco-free Kids. States and Localities That Have Restricted the Sale of Flavored Tobacco Products. Accessed: June 30, 2025. Available from: https://assets.tobaccofreekids.org/factsheets/0398.pdf

Ref. 1177. Whitacre TR, et al. (2025) Tob Control. Available from: https://doi.org/10.1136/tc-2024-058895

Ref. 1178. Kyriakos CN, et al. (2025) Tob Control, 34: 239. Available from: https://doi.org/10.1136/tc-2023-058174

Ref. 1179. Clark D, et al. (2024) Public Health Rep: 333549241300095. Available from: https://doi.org/10.1177/00333549241300095

Ref. 1180. Congress.gov. US Food and Drug Administration (FDA) Regulation of Electronic Nicotine Delivery Systems (ENDS): Background and Selected Policy Issues. Accessed: June 30, 2025. Available from: https://www.congress.gov/crs-product/R48483

Ref. 1181. Energy & Commerce Committee Democrats. Hearing on “Evaluating FDA Human Foods and Tobacco Programs”. Accessed: June 30, 2025. Available from: https://democrats-energycommerce.house.gov/committee-activity/hearings/hearing-evaluating-fda-human-foods-and-tobacco-programs

Ref. 1182. US Food and Drug Administration. FDA Authorizes Marketing of 20 ZYN Nicotine Pouch Products after Extensive Scientific Review. Accessed: June 30, 2025. Available from: https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-20-zyn-nicotine-pouch-products-after-extensive-scientific-review

Ref. 1183. FDA Center for Tobacco Products. FDA Tobacco Education & Prevention Resources: Posters, Flyers, & More | FDA Authorized E-Cigarette Products. Accessed: June 30, 2025. Available from: https://digitalmedia.hhs.gov/tobacco/print_materials/CTP-250?locale=en

Ref. 1184. US Food and Drug Administration. FDA Issues Final Rule Increasing the Minimum Age for Certain Restrictions on Tobacco Sales. Accessed: June 30, 2025. Available from: https://www.fda.gov/news-events/press-announcements/fda-issues-final-rule-increasing-minimum-age-certain-restrictions-tobacco-sales

Ref. 1185. Federal Registrar. Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products. Accessed: June 30, 2025. Available from: https://www.federalregister.gov/documents/2025/01/16/2025-00397/tobacco-product-standard-for-nicotine-yield-of-cigarettes-and-certain-other-combusted-tobacco

Ref. 1186. US Food asnd Drug Administration. Justice Department and FDA Announce Federal Multi-Agency Task Force to Curb the Distribution and Sale of Illegal E-Cigarettes. Accessed: June 30, 2025. Available from: https://www.fda.gov/news-events/press-announcements/justice-department-and-fda-announce-federal-multi-agency-task-force-curb-distribution-and-sale

Ref. 1187. Truth Initiative. US retail sales data show 86% of e-cigarette sales are for illegal products. Accessed: June 30, 2-25. Available from: https://truthinitiative.org/research-resources/tobacco-industry-marketing/us-retail-sales-data-show-86-e-cigarette-sales-are

Ref. 1188. US Food and Drug Administration. A Year in Review: FDA’s Progress on Tobacco Product Regulation in 2024. Accessed: June 30, 2025. Available from: https://www.fda.gov/tobacco-products/ctp-newsroom/year-review-fdas-progress-tobacco-product-regulation-2024

Ref. 1189. MacMonegle A, et al. (2025) Am J Prev Med. Available from: https://doi.org/10.1016/j.amepre.2025.02.015

Ref. 1190. Mann NH, et al. (2025) Nicotine Tob Res, 27: 326. Available from: https://doi.org/10.1093/ntr/ntae164

Ref. 1191. Centers for Disease Control and Prevention. CDC-RFA-DP20-2001: National and State Tobacco Control Program | Smoking and Tobacco Use. Accessed: June 30, 2025. Available from: https://www.cdc.gov/tobacco/php/foa/national-state-tobacco-control-program.html

Ref. 1192. Centers for Disease Control and Prevention. About the Office on Smoking and Health | National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). Accessed: June 30, 2025. Available from: https://www.cdc.gov/nccdphp/divisions-offices/about-the-office-on-smoking-and-health.html

Ref. 1193. Centers for Disease Control and Prevention. Surgeon General’s Report: Eliminating Tobacco-Related Disease and Death: Addressing Disparities. Accessed: June 30, 2025. Available from: https://archive.cdc.gov/#/details?url=https://www.cdc.gov/tobacco-surgeon-general-reports/about/2024-end-tobacco-disparities.html

Ref. 1194. Healthy People 2030. Social Determinants of Health. Accessed: June 30, 2025. Available from: https://odphp.health.gov/healthypeople/priority-areas/social-determinants-health

Ref. 1195. United Nations News Center. Environmental racism in Louisiana’s ‘Cancer Alley’, must end, say UN human rights experts. Accessed: June 30, 2025. Available from: https://news.un.org/en/story/2021/03/1086172

Ref. 1196. James W, et al. (2012) Int J Environ Res Public Health, 9: 4365. Available from: https://doi.org/10.3390/ijerph9124365

Ref. 1197. Gochfeld M, et al. (2011) Am J Public Health, 101 Suppl 1: S53. Available from: https://doi.org/10.2105/AJPH.2011.300121

Ref. 1198. Centers for Disease Control and Prevention. Cancer Survivors. Accessed: June 30, 2025. Available from: https://www.cdc.gov/cancer-survivors/index.html

Ref. 1199. National Cancer Institute. Childhood Cancer Survivor Study: An Overview. Accessed: June 30, 2025. Available from: https://www.cancer.gov/types/childhood-cancers/ccss

Ref. 1200. National Cancer Institute. Childhood Cancer Data Initiative (CCDI). Accessed: June 12, 2025. Available from: https://www.cancer.gov/research/areas/childhood/childhood-cancer-data-initiative

Ref. 1201. Children’s Oncology Group. Survivorship Guidelines. Accessed: June 30, 2025. Available from: https://childrensoncologygroup.org/survivorshipguidelines

Ref. 1202. St. Jude Children Research Hospital. CCSS. Childhood Cancer Survivor Study. Accessed: June 30, 2025. Available from: https://ccss.stjude.org/

Ref. 1203. Parikh RB, et al. (2022) J Natl Cancer Inst, 114: 1338. Available from: https://doi.org/10.1093/jnci/djac108

Ref. 1204. Bradley CJ, et al. (2022) J Natl Cancer Inst, 114: 1065. Available from: https://doi.org/10.1093/jnci/djac086